[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 191
1. Hofer MD, Chang MC, Hirko KA, Rubin MA, Nosé V: Immunohistochemical and clinicopathological correlation of the metastasis-associated gene 1 (MTA1) expression in benign and malignant pancreatic endocrine tumors. Mod Pathol; 2009 Jul;22(7):933-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical and clinicopathological correlation of the metastasis-associated gene 1 (MTA1) expression in benign and malignant pancreatic endocrine tumors.
  • Pancreatic endocrine tumors are rare tumors with unpredictable clinical behavior.
  • No histological features or immunohistochemical markers reliably predict malignant progression and the molecular basis of progression of pancreatic endocrine tumors remains unknown.
  • The metastasis-associated gene 1 is thought to play a role in transcription repression and estrogen receptor interaction and is overexpressed in several human cancers, including endocrine neoplasms.
  • The purpose of this study was to analyze the expression of metastasis-associated gene 1 in pancreatic endocrine tumors for its possible role in malignant progression.
  • Twenty-seven pancreatic endocrine tumors were identified from our archive.
  • The clinical follow-up data were examined and tumors were classified according to the 2004 World Health Organization criteria as benign behavior (WHO 1.1), uncertain behavior (WHO 1.2), well-differentiated endocrine carcinoma (WHO 2), and poorly differentiated endocrine carcinoma (WHO 3).
  • Metastasis-associated gene 1 expression was significantly higher in malignant tumors (n=17) with a mean staining intensity of 3.8 compared with 2.9 in benign tumors (n=10, P=0.046).
  • The expression levels were significantly associated with WHO class (P=0.028), as well as size of tumor (P=0.029), and mitotic rate (P=0.035).
  • We show that metastasis-associated gene 1 expression is significantly associated with malignant behavior in pancreatic endocrine tumors.
  • This may suggest a potential role for metastasis-associated gene 1 in the malignant progression and metastasis and its use as biomarker for malignant pancreatic endocrine tumors.
  • [MeSH-major] Adenoma, Islet Cell / enzymology. Carcinoma, Islet Cell / enzymology. Histone Deacetylases / metabolism. Islets of Langerhans / enzymology. Pancreatic Neoplasms / enzymology. Repressor Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19377441.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Repressor Proteins; EC 3.5.1.- / Mta1 protein, human; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


2. Choi YJ, Yun JS, Kim DH: Clinical and ultrasound features of cytology diagnosed follicular neoplasm. Endocr J; 2009;56(3):383-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and ultrasound features of cytology diagnosed follicular neoplasm.
  • The purpose of this study was to identify clinical and ultrasound (US) features of malignancy in patients using cytological results of follicular neoplasm (FN) in the thyroid.
  • Patient histopathology, age, sex, tumor size, and US characteristics and the color flow pattern of the lesions were analyzed and compared between benign and carcinomas.
  • Benign included 78 FA, 8 atypical FA, and 3 Hurthle cell adenomas.
  • The difference of shape, margin, the presence of a halo, internal content, and calcifications was not statistically significant (p value =0.05).
  • [MeSH-major] Adenocarcinoma, Follicular / ultrasonography. Thyroid Neoplasms / ultrasonography
  • [MeSH-minor] Adenoma, Oxyphilic / pathology. Adult. Aged. Female. Humans. Male. Middle Aged. Thyroid Gland / pathology. Thyroid Gland / ultrasonography. Ultrasonography, Doppler, Color

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19164864.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Timmers HJ, Brouwers FM, Hermus AR, Sweep FC, Verhofstad AA, Verbeek AL, Pacak K, Lenders JW: Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma. Endocr Relat Cancer; 2008 Dec;15(4):1127-33
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma.
  • The treatment of choice for non-metastatic pheochromocytoma is surgical resection.
  • Its goals are to abolish catecholamine hypersecretion, normalize blood pressure, and prevent further tumor growth or progression to metastatic disease.
  • We here report a retrospective study on the long-term outcome after surgery for apparently benign pheochromocytoma at the Radboud University Nijmegen Medical Centre.
  • Survival was compared with survival of a matched reference population.
  • Two patients experienced a benign recurrence. Mean+/-s.d. follow-up was 10.2+/-7.5 (median 9, range 1-38) years.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / surgery. Cardiovascular Diseases / mortality. Life Expectancy. Pheochromocytoma / secondary. Pheochromocytoma / surgery
  • [MeSH-minor] Adult. Aged. Blood Pressure. Catecholamines / blood. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824558.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Catecholamines
  •  go-up   go-down


Advertisement
4. Imai Y, Taketani T, Maemura K, Takeda N, Harada T, Nojiri T, Kawanami D, Monzen K, Hayashi D, Murakawa Y, Ohno M, Hirata Y, Yamazaki T, Takamoto S, Nagai R: Genetic analysis in a patient with recurrent cardiac myxoma and endocrinopathy. Circ J; 2005 Aug;69(8):994-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 60 year-old male was referred for treatment of a cardiac myxoma in the right atrium.
  • He had a past history of left atrial cardiac myxoma at age 49 and pituitary microadenoma related to acromegaly at age 55.
  • He did not have a family history of cardiac neoplasm or endocrinopathy.
  • The intracardiac tumor was resected and its pathology was compatible with myxoma.
  • A diagnosis of Carney complex (CNC) was made because the diagnostic criteria of this neoplastic syndrome were satisfied by the presence of recurrent cardiac myxoma, endocrine tumor and spotty skin pigmentation.
  • Although it is the most common, usually benign, cardiac tumor, myxoma can cause a critical clinical situation and thus detecting the PRKAR1A mutation can assist with prognosis.
  • [MeSH-major] Endocrine Gland Neoplasms / genetics. Heart Neoplasms / genetics. Mutation. Myxoma / genetics. Proteins / genetics
  • [MeSH-minor] Acromegaly / complications. Acromegaly / diagnosis. Acromegaly / genetics. Cyclic AMP-Dependent Protein Kinase RIalpha Subunit. Cyclic AMP-Dependent Protein Kinases. Humans. Male. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16041174.001).
  • [ISSN] 1346-9843
  • [Journal-full-title] Circulation journal : official journal of the Japanese Circulation Society
  • [ISO-abbreviation] Circ. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; 0 / PRKAR1A protein, human; 0 / Proteins; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases
  •  go-up   go-down


5. Avcu S, Ozen O, Bulut MD, Bora A: Hepatic metastases of primary jejunal carcinoid tumor: A case report with radiological findings. N Am J Med Sci; 2009 Nov;1(6):305-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic metastases of primary jejunal carcinoid tumor: A case report with radiological findings.
  • CONTEXT: Carcinoid tumors represent a group of well-differentiated tumors originating from the diffuse endocrine system outside the pancreas and thyroid.
  • Various sites of origin of this neoplasm are appendix - 30-45%, small bowel - 25-35% (duodenum 2%, jejunum 7%, ileum 91%, multiple sites 15-35%), rectum 10-15%, caecum - 5%, and stomach - 0.5%.
  • CASE REPORT: Here we report a case of primary jejunal carcinoid tumor in a 66-year-old woman metastasizing to liver with ultrasonography, computed tomography, and diffusion-weighted magnetic resonance imaging (DWI) findings.
  • CONCLUSION: Primary jejunal carcinoid tumor is a rare entity.
  • DWI can help in the differential diagnosis of hepatic hypervascular metastatic mass lesions from benign ones, as well as in the diagnosis of carcinoid tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22666712.001).
  • [ISSN] 2250-1541
  • [Journal-full-title] North American journal of medical sciences
  • [ISO-abbreviation] N Am J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3364631
  • [Keywords] NOTNLM ; Carcinoid / diffusion weighted MRI / jejunum / metastases / small bowel
  •  go-up   go-down


6. Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos AP, Orlandi F, Papotti M: Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer; 2005 Jun;12(2):305-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.
  • The distinction of benign from malignant follicular thyroid neoplasms remains a difficult task in diagnostic fine-needle aspiration cytology, and some discrepant results have been reported for the individual immunocytochemical markers of malignancy proposed so far.
  • The aim of this study was to test if the combined use of a panel of markers could improve the diagnostic accuracy in the preoperative cytological evaluation of 'follicular neoplasms' in an attempt to reduce the number of thyroidectomies performed for benign lesions.
  • The immunocytochemical expression of galectin-3, HBME-1, thyroperoxidase, cytokeratin-19 and keratan-sulfate was retrospectively analyzed in 125 consecutive fine-needle aspiration samples (cell blocks) of indeterminate diagnoses of 'follicular thyroid neoplasm', and compared with their corresponding surgical specimens, including 33 follicular carcinomas, 42 papillary carcinomas and 50 follicular adenomas.
  • The use of these two markers sequentially in non-oncocytic lesions (testing HBME-1 as a second marker whenever galectin-3 proved negative) increased the sensitivity and specificity up to 97% and 95% respectively.
  • Our data showed that, as compared with the use of single markers, the sequential combination of two markers represents the most accurate immunohistochemical panel in managing patients with a fine-needle aspiration biopsy diagnosis of 'follicular neoplasms', especially in otherwise controversial categories such as oncocytic tumours.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Biomarkers, Tumor / analysis. Immunohistochemistry. Thyroid Gland / pathology. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947105.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


7. Mohan H, Garg S, Punia RP, Dalal A: Combined serous cystadenoma and pancreatic endocrine neoplasm. A case report with a brief review of the literature. JOP; 2007;8(4):453-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined serous cystadenoma and pancreatic endocrine neoplasm. A case report with a brief review of the literature.
  • CONTEXT: The presence of a combined serous cystadenoma and pancreatic endocrine neoplasm is a distinct clinicopathological entity rather than the incidental concurrence of two separate entities.
  • CASE REPORT: We report the case of a 52-year-old woman admitted to our hospital who had suffered from epigastric pain, nausea and vomiting for 4 months.
  • The diagnosis of combined microcystic adenoma and pancreatic endocrine neoplasm was made.
  • The coexistence of pancreatic endocrine neoplasms with potential malignant behavior may be overshadowed by obvious benign tumors such as a microcystic serous cystadenoma.
  • The malignant potential and prognostic features of this neoplasm require long-term follow-up and additional data from subsequent reports of such cases.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / complications. Cystadenoma, Serous / complications. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17625299.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 13
  •  go-up   go-down


8. Serra S, Asa SL, Bamberger AM, Wagener C, Chetty R: CEACAM1 expression in pancreatic endocrine tumors. Appl Immunohistochem Mol Morphol; 2009 Jul;17(4):286-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CEACAM1 expression in pancreatic endocrine tumors.
  • The aim of this study was to examine the expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in pancreatic endocrine tumors (PETs) and to correlate it with clinicopathologic parameters.
  • Sixty-nine PETs were examined for tumor size, necrosis, local peripancreatic invasion and lymphovascular invasion, lymph node, and liver metastasis.
  • A tissue microarray was constructed and stained with an extensive panel of endocrine markers and CEACAM1.
  • Twenty-nine tumors were from males and 40 from females, age range: 23 to 80 years (mean 52.4 y), tumor size ranged from 0.8 to 11 cm (mean 3.5 cm), 8 patients had multiple endocrine neoplasia 1 syndrome, and 1 had von Hippel-Lindau disease.
  • Benign tumors and PETs of uncertain malignant behavior were more frequently CEACAM1-negative and low-grade malignant cases were CEACAM1 positive (27 of 29 cases) (P=0.001).

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19349857.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD66 antigens; 0 / Cell Adhesion Molecules; 0 / Neoplasm Proteins
  •  go-up   go-down


9. Ku YM, Shin SS, Lee CH, Semelka RC: Magnetic resonance imaging of cystic and endocrine pancreatic neoplasms. Top Magn Reson Imaging; 2009 Feb;20(1):11-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of cystic and endocrine pancreatic neoplasms.
  • This article describes the appearance of miscellaneous cystic and endocrine neoplasms using magnetic resonance imaging (MRI).
  • Magnetic resonance imaging is a useful diagnostic modality in the assessment of various pancreatic neoplasms.
  • Pancreatic endocrine tumors are moderately low in signal intensity on T1-weighted fat-suppressed images and moderately high in signal intensity on T2-weighted fat-suppressed images and demonstrate homogeneous, ring, or diffuse heterogeneous enhancement on immediate postgadolinium gradient echo images.
  • Cystic pancreatic neoplasms, including intraductal papillary mucinous neoplasm, are well demonstrated and subcategorized according to their characteristic cystic configurations on MRI and MR cholangiopancreatography images.
  • Mucinous cystic neoplasms usually appear as multilocular cystic masses, with benign forms of macrocystic tumors possessing uniform thickness septations and malignant forms exhibiting irregular septations and tumor nodules.
  • The presence of tumor stroma, invasion of adjacent tissue, or liver metastases can be assessed by MRI.
  • The connection between the pancreatic duct and the cystic tumor is usually well shown on MR cholangiopancreatography images.
  • [MeSH-major] Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Cholangiopancreatography, Magnetic Resonance / methods. Cholangiopancreatography, Magnetic Resonance / trends. Image Enhancement / methods. Pancreas / pathology. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19687721.001).
  • [ISSN] 1536-1004
  • [Journal-full-title] Topics in magnetic resonance imaging : TMRI
  • [ISO-abbreviation] Top Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


10. Nodit L, McGrath KM, Zahid M, Jani N, Schoedel KE, Ohori NP, Carty S, Finkelstein S, Khalid A: Endoscopic ultrasound-guided fine needle aspirate microsatellite loss analysis and pancreatic endocrine tumor outcome. Clin Gastroenterol Hepatol; 2006 Dec;4(12):1474-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic ultrasound-guided fine needle aspirate microsatellite loss analysis and pancreatic endocrine tumor outcome.
  • BACKGROUND & AIMS: The clinical course of pancreatic endocrine tumor (PET) varies depending on tumor aggressiveness, disease extent, and possibly accumulated molecular alterations.
  • Representative tumor cells were microdissected from the FNA material.
  • Thirteen were classified histologically as benign PET limited to the pancreas and 12 as malignant PET (invasive or metastatic).
  • The mean FAL in the benign and malignant PET was 0.03 and 0.37 (P<.0001), respectively.
  • [MeSH-major] DNA, Neoplasm / analysis. Endoscopy, Digestive System / methods. Loss of Heterozygosity / genetics. Microsatellite Repeats / genetics. Pancreatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16996803.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


11. Goh BK, Ooi LL, Kumarasinghe MP, Tan YM, Cheow PC, Chow PK, Chung YF, Wong WK: Clinicopathological features of patients with concomitant intraductal papillary mucinous neoplasm of the pancreas and pancreatic endocrine neoplasm. Pancreatology; 2006;6(6):520-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of patients with concomitant intraductal papillary mucinous neoplasm of the pancreas and pancreatic endocrine neoplasm.
  • BACKGROUND/AIMS: The occurrence of concomitant pancreatic endocrine neoplasm (PEN) and intraductal papillary neoplasm (IPMN) of the pancreas has rarely been reported.
  • The median size of the endocrine neoplasms was 14 mm (range 2-30) and they occurred in the head (n = 3), body (n = 2) and tail (n = 5).
  • Seven of the PENs were classified as benign, 2 were potentially malignant, and 1 was frankly malignant with lymph node involvement.
  • None of the endocrine neoplasms were functioning.
  • Five of these neoplasms were benign, 2 were borderline and 3 were malignant (1 carcinoma in situ).
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Neuroendocrine / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Neoplasms, Second Primary / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Chromogranins / metabolism. Female. Humans. Male. Middle Aged. Synaptophysin / metabolism. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel and IAP.
  • (PMID = 17124434.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranins; 0 / Synaptophysin
  •  go-up   go-down


12. Ghosh S, Joy R, Hickey S: Rare presentation of laryngeal neuroma in a patient with multiple endocrine neoplasia type two B. J Laryngol Otol; 2008 Sep;122(9):1012-4
Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare presentation of laryngeal neuroma in a patient with multiple endocrine neoplasia type two B.
  • OBJECTIVE: We present a rare case of laryngeal mucosal neuroma, and its management, in a patient with multiple endocrine neoplasia type 2 B.
  • METHOD: We present a case report and a review of the world literature concerning laryngeal mucosal neuroma and its association with multiple endocrine neoplasia type 2 B.
  • CASE REPORT: An 11-year-old girl was diagnosed with multiple endocrine neoplasia type 2 B on the basis of clinical presentation and genetic testing.
  • Biopsies taken at the time were reported as showing benign mucosal neuromas.
  • CONCLUSION: Multiple endocrine neoplasia syndromes are inherited autosomal cancer syndromes.
  • Laryngeal mucosal neuroma can manifest as potentially airway compromising lesions in patients with multiple endocrine neoplasia type 2 B.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Multiple Endocrine Neoplasia Type 2b / complications. Neuroma / pathology
  • [MeSH-minor] Child. Female. Humans. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17666129.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 9
  •  go-up   go-down


13. Bordi C, D'Adda T, Azzoni C, Pizzi S, Bottarelli L, Mormandi F, Antonetti T, Luong TV, Rindi G: Criteria for malignancy in gastrointestinal endocrine tumors. Endocr Pathol; 2006;17(2):119-29
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Criteria for malignancy in gastrointestinal endocrine tumors.
  • In contrast with the large amount of data generated from endocrine tumors of the pancreas, sparse and mostly unconfirmed data are available on the criteria for the assessment of malignancy risk and patient outcome in endocrine tumors of the gastrointestinal tract.
  • In these conditions the 2000 WHO classification with its standardized scheme of pathologic report constitutes a framework facilitating the assessment of tumor malignancy and has been regarded as useful for clinical purposes, providing the basis for proper management of the patients and for the design of treatment protocols.
  • The classification is based on a combination of pathological and clinical features with parameters specific for each organ in which the endocrine tumors originate.
  • (1) well-differentiated endocrine tumors, further subdivided into tumors with benign and with uncertain behavior;.
  • (2) well-differentiated endocrine carcinomas, low grade; and (3) poorly differentiated endocrine carcinomas, high grade.
  • In this review the differential tumor characteristics between the different categories are summarized.
  • Moreover, the relevance of additional features with respect to tumor prognostication, chiefly the Ki-67 proliferation index and malignancy-associated genetic changes, is discussed with emphasis on the discrepancies emerging between tumors of foregut and of midgut origin.
  • [MeSH-major] Endocrine Gland Neoplasms / classification. Endocrine Gland Neoplasms / diagnosis. Gastrointestinal Neoplasms / classification. Gastrointestinal Neoplasms / diagnosis. Neoplasm Invasiveness / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Ki-67 Antigen. Mitotic Index. Prognosis. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroendocrinology. 2004;80(6):394-424 [15838182.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2633-42 [12039924.001]
  • [Cites] Virchows Arch. 1995;425(6):547-60 [7697211.001]
  • [Cites] Histopathology. 2004 Oct;45(4):384-92 [15469477.001]
  • [Cites] World J Surg. 1998 Mar;22(3):309-18 [9494425.001]
  • [Cites] Q J Nucl Med. 2000 Mar;44(1):3-12 [10932597.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):1903-11 [11395364.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1787-94 [10595906.001]
  • [Cites] Tumour Biol. 1992;13(1-2):27-35 [1317054.001]
  • [Cites] Hum Pathol. 2001 Oct;32(10):1094-101 [11679944.001]
  • [Cites] J Pathol. 2002 Apr;196(4):401-7 [11920735.001]
  • [Cites] Yale J Biol Med. 1998 May-Aug;71(3-4):273-84 [10461358.001]
  • [Cites] Cancer. 1971 Oct;28(4):990-8 [4106849.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):285-92 [11196176.001]
  • [Cites] Virchows Arch. 1996 Dec;429(6):323-33 [8982376.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Dec;32(4):364-72 [11746977.001]
  • [Cites] Hum Pathol. 1988 May;19(5):580-5 [2453443.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1803-8 [11337378.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Nov;26(3):258-64 [10502325.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):706-11 [14608896.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1273-82 [12973852.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1145-53 [15316313.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1988;413(5):387-98 [2845642.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1765-75 [15755998.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):311-5 [9927038.001]
  • [Cites] J Pathol. 1998 Sep;186(1):41-50 [9875139.001]
  • [Cites] Gastroenterology. 1999 Mar;116(3):532-42 [10029611.001]
  • [Cites] Hum Pathol. 1996 Nov;27(11):1124-34 [8912819.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:1-12 [15153415.001]
  • [Cites] Am J Pathol. 1989 Dec;135(6):1065-72 [2480712.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):233-45 [9665484.001]
  • [Cites] J Pathol. 1998 Aug;185(4):389-93 [9828837.001]
  • [Cites] Am J Surg Pathol. 2001 Apr;25(4):472-8 [11257621.001]
  • [Cites] Cancer. 1983 Jan 15;51(2):277-82 [6821817.001]
  • [Cites] Am J Surg Pathol. 1995;19 Suppl 1:S8-19 [7762739.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1991;419(6):463-8 [1750193.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):532-8 [11920612.001]
  • [Cites] J Clin Invest. 1997 Jul 15;100(2):404-10 [9218518.001]
  • [Cites] J Pathol. 1999 Nov;189(3):394-401 [10547602.001]
  • [Cites] J Pathol. 2001 Aug;194(4):451-8 [11523053.001]
  • [Cites] J Pathol. 2005 Aug;206(4):409-16 [15887288.001]
  • [Cites] Am J Clin Pathol. 1990 Feb;93(2):273-6 [1689098.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):437-50 [14713256.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1448-53 [9326914.001]
  • [Cites] Expert Rev Mol Diagn. 2001 Sep;1(3):323-33 [11901838.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):947-57 [14871972.001]
  • (PMID = 17159244.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  • [Number-of-references] 51
  •  go-up   go-down


14. Angeles-Angeles A: [Endocrine neoplasm of the stomach. Study of thirteen cases]. Gac Med Mex; 2005 May-Jun;141(3):207-13
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endocrine neoplasm of the stomach. Study of thirteen cases].
  • [Transliterated title] Tumores endocrinos del estómago. Análisis de 13 casos.
  • A Thirteen patients with primary endocrine neoplasm of the stomach were studied for 20 years.
  • These two forms of neoplasm showed important differences: those associated with atrophic gastritis had hypergastrinemia, all of the multiple small tumors confined to the corpus and fundus were well differentiated carcinoids associated with intestinal metaplasia and G cell hyperplasia in antrum and ECL cell hyperplasia in corpus and fundus.
  • Tumors were clinically benign, with an excellent prognosis.
  • All patients are currently alive with no evidence of neoplasm.
  • Two patients died as a consequence of the neoplasm; all of them were moderately differentiated and in none of the cases we found evidence of endocrine hyperplasia.
  • All were positive for generic endocrine markers and were focally positive to some of the specific hormone markers.
  • [MeSH-major] Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16025986.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


15. Hirono S, Tani M, Kawai M, Ina S, Nishioka R, Miyazawa M, Shimizu A, Uchiyama K, Yamaue H: A central pancreatectomy for benign or low-grade malignant neoplasms. J Gastrointest Surg; 2009 Sep;13(9):1659-65
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A central pancreatectomy for benign or low-grade malignant neoplasms.
  • INTRODUCTION: A central pancreatectomy is a parenchyma-sparing procedure that is performed to reduce long-term endocrine and exocrine insufficiency.
  • METHOD: In this study, we analyzed the perioperative course, the frequency of postoperative onset of diabetes mellitus, and long-term change of body weight in patients undergoing a central pancreatectomy, in comparison to the patients undergoing a distal pancreatectomy for low-grade neoplasms including cystic neoplasms and neuroendocrine tumors.
  • CONCLUSION: A central pancreatectomy is a safe procedure for the treatment of low-grade malignant neoplasms in the pancreatic body; the rate of onset of diabetes is minimal, and the body weight improves early in the postoperative course.
  • [MeSH-major] Body Weight. Diabetes Mellitus / etiology. Pancreatectomy / methods. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Databases, Factual. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Neuroendocrine Tumors / mortality. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / surgery. Pancreatic Cyst / mortality. Pancreatic Cyst / pathology. Pancreatic Cyst / surgery. Postoperative Complications / diagnosis. Postoperative Complications / epidemiology. Probability. Prospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Body Weight.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1999 May;229(5):693-8; discussion 698-700 [10235528.001]
  • [Cites] Langenbecks Arch Surg. 2005 Jun;390(3):266-71 [15864637.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):316-20 [16495694.001]
  • [Cites] Ann Surg. 2006 Dec;244(6):909-18; discussion 918-20 [17122616.001]
  • [Cites] Ann Surg. 2002 Nov;236(5):612-8 [12409667.001]
  • [Cites] Arch Surg. 2004 Feb;139(2):188-92 [14769579.001]
  • [Cites] J Gastrointest Surg. 2008 Sep;12(9):1548-53 [18543045.001]
  • [Cites] Arch Surg. 2008 Feb;143(2):175-80; discussion 180-1 [18283143.001]
  • [Cites] Surg Gynecol Obstet. 1959 Oct;109:473-8 [14416087.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14 (6):600-3 [18040629.001]
  • [Cites] Arch Surg. 2009 Apr;144(4):345-9; discussion 349-50 [19380648.001]
  • [Cites] J Gastrointest Surg. 2006 Jun;10(6):804-12 [16769536.001]
  • [Cites] Arch Surg. 1995 Mar;130(3):295-9; discussion 299-300 [7887797.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):69-76 [17592293.001]
  • [Cites] Dig Surg. 2004;21(1):48-53 [14707393.001]
  • [Cites] Mem Acad Chir (Paris). 1957 Nov 13-20;83(27-28):869-71 [13503655.001]
  • [Cites] J Gastrointest Surg. 2007 Mar;11(3):364-76 [17458612.001]
  • [Cites] Dig Surg. 2003;20(6):506-10 [14506331.001]
  • [Cites] Diabetes. 1974 May;23(5):424-32 [4598091.001]
  • [Cites] J Gastrointest Surg. 2004 Jul-Aug;8(5):532-8 [15239986.001]
  • [Cites] Surgery. 2005 Jul;138(1):8-13 [16003309.001]
  • [Cites] Ann Surg. 2006 Jul;244(1):1-7 [16794381.001]
  • [Cites] J Gastrointest Surg. 1998 Nov-Dec;2(6):509-16; discussion 516-7 [10457309.001]
  • [Cites] Diabetes. 2008 Jan;57(1):142-9 [17959931.001]
  • (PMID = 19488821.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Marrache F, Cazals-Hatem D, Kianmanesh R, Palazzo L, Couvelard A, O'Toole D, Maire F, Hammel P, Levy P, Sauvanet A, Ruszniewski P: Endocrine tumor and intraductal papillary mucinous neoplasm of the pancreas: a fortuitous association? Pancreas; 2005 Jul;31(1):79-83
Hazardous Substances Data Bank. GLUCAGON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine tumor and intraductal papillary mucinous neoplasm of the pancreas: a fortuitous association?
  • OBJECTIVES: Pancreatic endocrine tumors (PETs) and intraductal papillary mucinous neoplasms (IPMNs) of the pancreas are rare diseases of the pancreas.
  • Cases of association of endocrine and exocrine neoplasms of the pancreas have been reported, corresponding to mixed or amphicrine tumors.
  • RESULTS: Preoperative diagnosis was unspecified pancreatic tumor (n = 1), IPMN (n = 2), and association of PET and IPMN (n = 3).
  • IPMN involved the main pancreatic duct in 4 patients and was classified as benign (n = 4), borderline (n = 1), or malignant noninvasive (n = 1).
  • CONCLUSION: This study describes a new aspect of endocrine-exocrine pancreatic neoplasm association.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Endocrine Gland Neoplasms / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968252.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Chromogranins; 9007-92-5 / Glucagon
  •  go-up   go-down


17. Portela-Gomes GM, Stridsberg M, Grimelius L, Rorstad O, Janson ET: Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas - predominance of receptor subtype 4. Endocr Pathol; 2007;18(2):79-85
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas - predominance of receptor subtype 4.
  • Insulinomas constitute a subgroup of pancreatic endocrine tumors showing B cell differentiation and clinical symptoms related to inappropriate insulin secretion (WHO).
  • Many endocrine tumors express somatostatin receptors (sstrs), which can be visualized by octreotide scintigraphy; however, about half of all insulinomas are reported to be negative.
  • In the present study, the immunoreactivity to all five human sstr was studied in ten benign and six malignant human insulinomas.
  • Sstr4 was the receptor subtype most frequently expressed in both benign and malignant tumors.
  • A difference in the immunohistochemical sstr5 expression pattern was seen between benign and malignant tumors: Three of the six malignant tumors, but none of the benign tumors, expressed sstr5.
  • The other receptor subtypes were expressed in low numbers with no difference between benign and malignant tumors.
  • The finding of a strong expression of sstr4 in both benign and malignant insulinomas suggests that this receptor subtype could be of importance for diagnostic and therapeutic use.
  • [MeSH-major] Insulinoma / genetics. Insulinoma / metabolism. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / metabolism. Receptors, Somatostatin / biosynthesis. Receptors, Somatostatin / genetics
  • [MeSH-minor] Animals. Blotting, Western. COS Cells. Cercopithecus aethiops. Electrophoresis, Polyacrylamide Gel. Humans. Immunohistochemistry. Membrane Proteins / biosynthesis. Membrane Proteins / genetics. Neoplasm Metastasis / genetics. Neoplasm Metastasis / pathology. Tissue Fixation. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endocrinol Invest. 2005;28(11 Suppl International):132-6 [16625862.001]
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Endocr Relat Cancer. 2006 Mar;13(1):69-78 [16601280.001]
  • [Cites] Virchows Arch. 2002 May;440(5):461-75 [12021920.001]
  • [Cites] Cancer Chemother Biol Response Modif. 2003;21:535-46 [15338762.001]
  • [Cites] Br J Surg. 2001 Jan;88(1):31-40 [11136306.001]
  • [Cites] Eur J Clin Invest. 1997 Aug;27(8):639-44 [9279525.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2315-9 [7907795.001]
  • [Cites] Surg Today. 2002;32(8):690-4 [12181718.001]
  • [Cites] Cell Physiol Biochem. 2002;12 (1):31-8 [11914546.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Sep 15;195(2):844-52 [8373420.001]
  • [Cites] Can J Biochem. 1974 Nov;52(11):1067-72 [4609582.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2534-41 [9667275.001]
  • [Cites] Med Oncol. 2003;20(1):59-67 [12665686.001]
  • [Cites] Mol Endocrinol. 1992 Dec;6(12):2136-42 [1337145.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3455-9 [8012966.001]
  • [Cites] J Clin Invest. 1994 Mar;93(3):1321-5 [8132773.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5353-60 [14602773.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):5969-77 [2168286.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1580-4 [7878022.001]
  • [Cites] Eur J Endocrinol. 2005 May;152(5):757-67 [15879362.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Jun;8(2):126-32 [10937060.001]
  • [Cites] Cancer Res. 1998 Jun 1;58(11):2375-8 [9622077.001]
  • [Cites] Gut. 2002 Jan;50(1):52-60 [11772967.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):233-45 [9665484.001]
  • [Cites] Eur J Endocrinol. 2002 May;146(5):707-16 [11980628.001]
  • [Cites] Front Neuroendocrinol. 1999 Jul;20(3):157-98 [10433861.001]
  • [Cites] Eur J Endocrinol. 2004 Jul;151(1):107-12 [15248829.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):251-5 [1346068.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Sep;82(9):3011-8 [9284735.001]
  • [Cites] J Nucl Med. 2000 Mar;41(3):459-62 [10716319.001]
  • [Cites] Mol Endocrinol. 1996 Dec;10(12):1688-96 [8961277.001]
  • (PMID = 17916997.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Receptors, Somatostatin; 0 / somatostatin receptor subtype-4
  •  go-up   go-down


18. Vanbeckevoort D: Solid pancreatic masses: benign or malignant. JBR-BTR; 2007 Nov-Dec;90(6):487-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid pancreatic masses: benign or malignant.
  • Solid masses in the pancreas mostly occur in the pancreatic head and may be related to inflammation due to chronic pancreatitis or may be caused by malignancy.
  • Ductal pancreatic carcinoma is the most common malignant pancreatic neoplasm, accounting for more than 90% of malignant solid pancreatic tumours.
  • Endocrine tumours represent only a minority of those tumours.
  • While endocrine tumours tend to exhibit symptoms earlier in the course of the disease (due to tumour-related hormone production), adenocarcinomas present in nearly all cases in advanced stages when curative resection is not feasible.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endocrine Gland Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Pancreatic Neoplasms / diagnosis. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376761.001).
  • [ISSN] 0302-7430
  • [Journal-full-title] JBR-BTR : organe de la Société royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR)
  • [ISO-abbreviation] JBR-BTR
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 13
  •  go-up   go-down


19. Ji Y, Zhu XZ, Lou WH, Wang DQ, Jin DY, Zeng MS, Zeng HY: [Clinicopathologic analysis of 92 cases of pancreatic cystic neoplasm]. Zhonghua Bing Li Xue Za Zhi; 2007 Mar;36(3):160-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic analysis of 92 cases of pancreatic cystic neoplasm].
  • OBJECTIVE: To study the clinicopathologic and immunohistochemical features of cystic neoplasms of the pancreas.
  • METHODS: Ninety-two cases of cystic neoplasm of pancreas were retrieved from the Department archival file during the period from 1999 to 2005.
  • They consisted of intraductal papillary mucinous neoplasm (36/92), serous cystic neoplasm (18/92), solid pseudopapillary tumor (18/92), mucinous cystic neoplasm (14/92), cystic pancreatic ductal adenocarcinoma (4/92) and cystic pancreatic endocrine neoplasm (2/92).
  • Immunohistochemical study revealed variable staining patterns, with frequent overlaps between different tumor types.
  • In general, serous cystic neoplasm expressed MUC1, while mucinous cystic neoplasm was positive for MUC-5AC, intraductal papillary mucinous neoplasm for MUC-2 and cystic pancreatic ductal adenocarcinoma for MUC-1.
  • On the other hand, solid pseudopapillary tumor expressed alpha-antitrypsin, alpha-antichymotrypsin, vimentin and progesterone receptor.
  • CONCLUSIONS: Accurate diagnosis of pancreatic cystic neoplasms requires correlation of clinical findings, radiologic examination, histologic features and immunostaining results.
  • Two-thirds of pancreatic cystic neoplasms are premalignant or malignant and warrant surgical resection, whereas the remaining one-third (including pseudocyst and serous cystadenoma) are benign and can be treated conservatively.
  • [MeSH-major] Mucin-1 / metabolism. Neoplasms, Cystic, Mucinous, and Serous / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Mucin 5AC / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17535681.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / MUC1 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-1
  •  go-up   go-down


20. He X, Wei Q, Zhang X, Xiao J, Jin X, Zhu Y, Cui B, Ning G: Immunohistochemical expression of CXCR4 in thyroid carcinomas and thyroid benign lesions. Pathol Res Pract; 2010 Oct 15;206(10):712-5
MedlinePlus Health Information. consumer health - Thyroid Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of CXCR4 in thyroid carcinomas and thyroid benign lesions.
  • In different tumor entities, expression of the chemokine receptor 4 (CXCR4) has been linked to tumor dissemination and poor prognosis.
  • The aim of this study was to examine the immunohistochemical expression of CXCR4 in thyroid carcinomas and thyroid benign lesions.
  • In our study, the CXCR4 expression of the thyroid carcinoma group (including 16 papillary thyroid carcinomas, 18 follicular thyroid carcinomas, 9 poorly differentiated thyroid carcinomas, and 7 medullary thyroid carcinomas) was found to be higher than in the benign lesion group (including 19 cases of Hashimoto's thyroiditis, 15 nodular goiters, and 50 follicular adenomas) (p<0.0001).
  • [MeSH-major] Biomarkers, Tumor / analysis. Immunohistochemistry. Receptors, CXCR4 / analysis. Thyroid Diseases / immunology
  • [MeSH-minor] Adenocarcinoma, Follicular. Adolescent. Adult. Aged. Carcinoma. Carcinoma, Neuroendocrine. Cell Differentiation. Child. Female. Goiter, Nodular / immunology. Hashimoto Disease / immunology. Humans. Male. Middle Aged. Neoplasm Invasiveness. Thyroid Neoplasms / immunology. Thyroid Neoplasms / pathology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20646838.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCR4 protein, human; 0 / Receptors, CXCR4; Thyroid cancer, medullary; Thyroid cancer, papillary
  •  go-up   go-down


21. Capelli P, Martignoni G, Pedica F, Falconi M, Antonello D, Malpeli G, Scarpa A: Endocrine neoplasms of the pancreas: pathologic and genetic features. Arch Pathol Lab Med; 2009 Mar;133(3):350-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine neoplasms of the pancreas: pathologic and genetic features.
  • CONTEXT: Pancreatic endocrine neoplasms (PENs) are diagnostically challenging tumors whose natural history is largely unknown.
  • Histopathology allows the distinction of 2 categories: poorly differentiated high-grade carcinomas and well-differentiated neoplasms.
  • CONCLUSIONS: The diagnosis of PEN is generally easy, but unusual features may induce misdiagnosis.
  • Immunohistochemistry solves the issue, provided that the possibility of a PEN has been considered.
  • Morphology allows the distinction of poorly differentiated aggressive carcinomas from well-differentiated neoplasms.
  • The World Health Organization classification criteria allow for the discernment of the latter into neoplasms and carcinomas with either benign or uncertain behavior.
  • The degree of genomic instability correlates with the aggressiveness of the neoplasm.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / genetics. Neoplasms, Glandular and Epithelial / pathology. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Gene Expression Regulation, Neoplastic. Gene Silencing. Humans. Neoplasm Staging. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260741.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MEN1 protein, human; 0 / Proto-Oncogene Proteins
  • [Number-of-references] 166
  •  go-up   go-down


22. Miyakoshi A, Dalley RW, Anzai Y: Magnetic resonance imaging of thyroid cancer. Top Magn Reson Imaging; 2007 Aug;18(4):293-302
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thyroid cancer is a unique malignancy arising from the endocrine system, and its nature is different from more common squamous cell carcinoma in the head and neck region.
  • Imaging findings of benign and malignant thyroid lesions overlap substantially, and differentiation may be difficult.
  • [MeSH-major] Magnetic Resonance Imaging. Neoplasm Staging. Thyroid Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17893594.001).
  • [ISSN] 0899-3459
  • [Journal-full-title] Topics in magnetic resonance imaging : TMRI
  • [ISO-abbreviation] Top Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


23. Niederle MB, Hackl M, Kaserer K, Niederle B: Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer; 2010 Dec;17(4):909-18
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters.
  • Using the current WHO classification, the tumor, nodes, metastases (TNM) staging and Ki67 grading and the standard diagnostic procedure proposed by the European Neuroendocrine Tumor Society (ENETS), GEP-NETs from 285 patients (male: 148; female: 137) were recorded.
  • The stomach (23%) was the main site, followed by appendix (21%), small intestine (15%) and rectum (14%).
  • Patients with appendiceal tumours were significantly younger than patients with tumours in any other site.
  • About 46.0% were classified as benign, 15.4% as uncertain, 31.9% as well differentiated malignant and 6.7% as poorly differentiated malignant.
  • Patients with benign or uncertain tumours were significantly younger than patients with malignant tumours.
  • NETs of the digestive tract are more common than previously reported; the majority show benign behaviour, are located in the stomach and are well differentiated.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Neuroendocrine Tumors / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Austria / epidemiology. Female. Histocytochemistry. Humans. Incidence. Male. Middle Aged. Neoplasm Staging / methods. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20702725.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Queiroga FL, Pérez-Alenza D, Silvan G, Peña L, Lopes CS, Illera JC: Serum and intratumoural GH and IGF-I concentrations: prognostic factors in the outcome of canine mammary cancer. Res Vet Sci; 2010 Dec;89(3):396-403
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hormonal determinations were done by enzyme immunoassays techniques validated for canine species in serum and tumour tissue from 32 bitches with CMT and in serum and normal mammary tissue from 10 controls.
  • Serum and tissular GH and IGF-I concentrations were significantly higher in the case of malignant tumour compared with benign and controls.
  • GH and IGF-I elevated concentrations were significantly associated with tumour relapse and/or metastases during follow-up and in dogs with reduced survival times; however these parameters were not independent prognostic factors in multivariate analysis.
  • This association demonstrates a link between high serum and intratumoural GH and IGF-I concentrations and a worse prognosis and opens the possibility to new anticancer endocrine therapies in dogs.
  • [MeSH-major] Breast Neoplasms / veterinary. Dog Diseases / diagnosis. Growth Hormone / blood. Insulin-Like Growth Factor I / analysis
  • [MeSH-minor] Animals. Breast / chemistry. Breast / pathology. Dogs. Estrogen Receptor alpha / analysis. Female. Immunoenzyme Techniques / veterinary. Neoplasm Metastasis. Prognosis. Prospective Studies. Receptors, Progesterone / analysis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20381105.001).
  • [ISSN] 1532-2661
  • [Journal-full-title] Research in veterinary science
  • [ISO-abbreviation] Res. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Receptors, Progesterone; 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone
  •  go-up   go-down


25. Cetani F, Ambrogini E, Viacava P, Pardi E, Fanelli G, Naccarato AG, Borsari S, Lemmi M, Berti P, Miccoli P, Pinchera A, Marcocci C: Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol; 2007 May;156(5):547-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?
  • The aim of our study was to extend parafibromin studies in a series of benign and malignant parathyroid tumors and cross-validate the results of immunohistochemistry with those of HRPT2 analysis.

  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17468190.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDC73 protein, human; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Proteins; 136601-57-5 / Cyclin D1
  •  go-up   go-down


26. Dhellemmes P, Vinchon M: Radical resection for craniopharyngiomas in children: surgical technique and clinical results. J Pediatr Endocrinol Metab; 2006 Apr;19 Suppl 1:329-35
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Craniopharyngiomas are benign suprasellar tumors; however, their tendency to recur after resection and the risks associated with aggressive tumor resection pose a surgical dilemma.
  • No patient died in the operative period; three patients died 6 months to 8 years after surgery of endocrine-related cause or sudden death.
  • Tumor progression occurred in 93% of cases after subtotal resection versus 43% after total resection.
  • Visual deficits were often stabilized or improved after surgery, but worsened in 30% because of surgical damage or tumor recurrence.
  • Hypothalamic damage was generally associated with intraventricular extension of the tumor recurrence and re-operations, especially through combined approaches.
  • [MeSH-major] Craniopharyngioma / surgery. Neurosurgical Procedures / methods. Pituitary Neoplasms / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Hormone Replacement Therapy. Humans. Male. Neoplasm Recurrence, Local / therapy. Neuropsychological Tests. Postoperative Care. Radiosurgery. Retrospective Studies. Rhenium / therapeutic use. Tomography, X-Ray Computed. Treatment Outcome. Visual Acuity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16700308.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 7440-15-5 / Rhenium
  •  go-up   go-down


27. Slater EP, Diehl SM, Langer P, Samans B, Ramaswamy A, Zielke A, Bartsch DK: Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur J Endocrinol; 2006 Apr;154(4):587-98
Hazardous Substances Data Bank. HYDROCORTISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Adrenocortical carcinoma (ACC) is a rare malignant neoplasm with extremely poor prognosis.
  • The comparative analysis by cDNA microarrays of gene-expression patterns of benign and malignant adrenocortical tumors allows us to identify new tumor-suppressor genes and proto-oncogenes underlying adrenocortical tumorigenesis.
  • DESIGN AND METHODS: Total RNA from fresh-frozen tissue of 10 ACC and 10 benign adrenocortical adenomas was isolated after histologic confirmation of neoplastic cellularity of at least 85%.
  • Amplified RNA of tumor and reference was used to synthesize Cy3- and Cy5-fluorescently labeled cDNA in a flip-color technique.
  • CONCLUSIONS: Comprehensive expression profiling of adrenocortical tumors by the cDNA microarray technique is a very powerful tool to elucidate the molecular steps associated with the tumorigenesis of these ill-defined neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16556722.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 4964P6T9RB / Aldosterone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


28. Christein JD, Smoot RL, Farnell MB: Central pancreatectomy: a technique for the resection of pancreatic neck lesions. Arch Surg; 2006 Mar;141(3):293-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although historically used for traumatic pancreatic transection and chronic pancreatitis, it currently is reserved for selective management of pancreatic neck lesions that are benign or have low malignant potential.
  • Our objectives were to describe the technique and determine the safety and effectiveness of central pancreatectomy in the excision of benign or low-malignant potential lesions of the pancreatic neck.
  • On follow-up, long-term endocrine and exocrine function were determined based on laboratory values and patient history.
  • Mean tumor size was 2.8 cm and mean operative time was 4.8 hours with a mean blood loss of 381 mL.
  • CONCLUSIONS: Central pancreatectomy may preserve endocrine and exocrine function.
  • The precise role of central pancreatectomy in the management of benign or low-malignant potential lesions of the neck of the pancreas remains in evolution.
  • [MeSH-major] Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenoma, Islet Cell / radiography. Adenoma, Islet Cell / surgery. Cystadenoma, Serous / radiography. Cystadenoma, Serous / surgery. Female. Humans. Liposarcoma / surgery. Male. Mesenteric Veins / surgery. Middle Aged. Neoplasm Recurrence, Local / surgery. Reoperation. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16549696.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Mukherjee R, Edwards J, Underwood MA, Bartlett JM: The relationship between angiogenesis and cyclooxygenase-2 expression in prostate cancer. BJU Int; 2005 Jul;96(1):62-6
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To test the hypothesis that angiogenesis in prostate cancer is associated with tumour invasion and metastasis, and that this is mediated through increased cyclooxygenase-2 (COX-2) expression.
  • PATIENTS AND METHODS: Angiogenesis was assessed in 105 patients with either prostate cancer (79) or benign prostatic hyperplasia (BPH, 26) and these data correlated with levels of COX-2 expression in the same dataset.
  • RESULTS: There was no difference in MVD in progressive tumour stages compared with BPH.
  • CONCLUSION: These data suggest that COX-2 drives tumour spread in prostate cancer by means other than the promotion of angiogenesis.
  • [MeSH-major] Neoplasm Proteins / metabolism. Neovascularization, Pathologic / pathology. Prostaglandin-Endoperoxide Synthases / metabolism. Prostatic Neoplasms / blood supply. Prostatic Neoplasms / enzymology
  • [MeSH-minor] Aged. Aged, 80 and over. Cyclooxygenase 2. Humans. Immunohistochemistry. Male. Membrane Proteins. Microcirculation. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Prostatic Hyperplasia / enzymology. Prostatic Hyperplasia / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15963122.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Neoplasm Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


30. Boninsegna L, Partelli S, D'Innocenzio MM, Capelli P, Scarpa A, Bassi C, Pederzoli P, Falconi M: Pancreatic cystic endocrine tumors: a different morphological entity associated with a less aggressive behavior. Neuroendocrinology; 2010;92(4):246-51
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic cystic endocrine tumors: a different morphological entity associated with a less aggressive behavior.
  • BACKGROUND: Cystic pancreatic endocrine tumors (CPETs) are rare lesions and their biological features have been scarcely investigated.
  • AIM: To compare clinical and pathological features of resected non-functioning sporadic CPETs (NF-CPETs) with solid pancreatic endocrine tumors (SPETs) in a single-institution experience.
  • METHODS: All patients with a pathologically confirmed diagnosis of sporadic non-functioning pancreatic endocrine tumors who underwent curative resection between 1990 and 2008 were included.
  • Univariate and multivariable analyses were performed to identify preoperative predictors of carcinoma (non-functioning pancreatic endocrine carcinoma).
  • RESULTS: Twenty-one (11.5%) patients with a histological diagnosis of NF-CPET were identified.
  • The median age was 60 years (IQR 46.5-73.5 years) and a diagnosis of carcinoma (non-functioning pancreatic endocrine carcinoma) was made in 3 (14.3%) cases.
  • The incidence of non-functioning pancreatic endocrine carcinoma was significantly lower in the NF-CPET versus the NF-SPET group (14.3 vs. 40.4%, p = 0.04).
  • By univariate analysis, preoperative predictors of non-functioning pancreatic endocrine carcinoma included the presence of symptoms (OR 3.96, 95% CI 2.06-7.63) and an increase in the absolute value of radiological diameter (OR 1.05, 95% CI 1.03-1.07).
  • CONCLUSIONS: NF-CPETs have a measurable propensity to be benign.
  • In those patients affected by small and asymptomatic NF-CPET a more conservative surgical approach or a follow-up policy could be considered.
  • [MeSH-major] Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / pathology. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Cohort Studies. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Pancreatectomy / methods. Pancreatic Cyst / diagnosis. Pancreatic Cyst / pathology. Survival Analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 20689265.001).
  • [ISSN] 1423-0194
  • [Journal-full-title] Neuroendocrinology
  • [ISO-abbreviation] Neuroendocrinology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


31. Tonelli F, Fratini G, Falchetti A, Nesi G, Brandi ML: Surgery for gastroenteropancreatic tumours in multiple endocrine neoplasia type 1: review and personal experience. J Intern Med; 2005 Jan;257(1):38-49
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery for gastroenteropancreatic tumours in multiple endocrine neoplasia type 1: review and personal experience.
  • Multiple endocrine neoplasia type 1 (MEN1) gastro-entero-pancreatic (GEP) tumours develop from the pancreatic islets and from the endocrine cells of the duodenal and gastric mucosa.
  • Even if GEP tumours have generally a benign course, a subgroup of them shows an aggressive behaviour and is a major cause of death amongst MEN1 patients.
  • Diagnosis of insulinoma should lead promptly to pancreatic surgery.
  • Cure rate for Zollinger-Ellison syndrome in MEN1 is low when surgery is limited to tumour enucleation or full thickness duodenal wall resection.
  • [MeSH-major] Gastrointestinal Neoplasms / surgery. Multiple Endocrine Neoplasia Type 1 / surgery
  • [MeSH-minor] Gastrinoma / surgery. Humans. Insulinoma / surgery. Neoplasm Metastasis / therapy. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods. Prognosis. Stomach Neoplasms / surgery. Time Factors


32. Varma V, Gandhi V, Bheerappa N, Sastry RA: Central pancreatectomy for neoplasm of mid pancreas - a report of four cases. Indian J Surg; 2008 Oct;70(5):237-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central pancreatectomy for neoplasm of mid pancreas - a report of four cases.
  • Central pancreatectomy (CP) originally done for pancreatic trauma and focal pancreatitis is recently being performed for benign and low grade malignant neoplasm of mid pancreas.
  • It offers the advantage of conserving pancreatic tissue and preserving gastroduodenal-biliary anatomy, important for maintenance of endocrine and exocrine pancreatic function.
  • Histology reported solid variant of serous cystadenoma (1), solid pseudopapillary tumor (1), focal pancreatitis (1) and ductal adenocarcinoma (1).
  • CP may be a viable option for mid pancreatic lesions of benign or low grade malignant potential.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1992 Dec;216(6):656-62 [1466619.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Ann Surg. 1999 May;229(5):693-8; discussion 698-700 [10235528.001]
  • [Cites] J Gastrointest Surg. 1998 Nov-Dec;2(6):509-16; discussion 516-7 [10457309.001]
  • [Cites] Arch Surg. 2000 May;135(5):517-23; discussion 523-4 [10807274.001]
  • [Cites] J Am Coll Surg. 2000 Jun;190(6):711-6 [10873007.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(5):453-5 [11180870.001]
  • [Cites] Surgery. 2005 Jul;138(1):8-13 [16003309.001]
  • [Cites] Ann Surg. 2006 Dec;244(6):909-18; discussion 918-20 [17122616.001]
  • (PMID = 23133071.001).
  • [ISSN] 0972-2068
  • [Journal-full-title] The Indian journal of surgery
  • [ISO-abbreviation] Indian J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3452409
  • [Keywords] NOTNLM ; Benign mid pancreatic lesion / Central Pancreatectomy / Endocrine and exocrine pancreatic function
  •  go-up   go-down


33. Blandamura S, Parenti A, Famengo B, Canesso A, Moschino P, Pasquali C, Pizzi S, Guzzardo V, Ninfo V: Three cases of pancreatic serous cystadenoma and endocrine tumour. J Clin Pathol; 2007 Mar;60(3):278-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three cases of pancreatic serous cystadenoma and endocrine tumour.
  • AIMS: To report three cases of serous cystadenoma and endocrine tumour in the same pancreas, to review the literature and to evaluate the clinicopathological features of the tumours.
  • RESULTS: Histological examination of the pancreas showed one serous oligocystic adenoma associated with a benign, well-differentiated endocrine tumour, one serous oligocystic adenoma associated with an endocrine microadenoma, and a von Hippel-Lindau-related cystic neoplasm with a well-differentiated endocrine carcinoma.
  • CONCLUSIONS: Serous cystadenoma associated with endocrine tumour shows some clinicopathological differences with respect to the two tumours considered separately, and with respect to von Hippel-Lindau-related cases, although there is no convincing evidence at present to justify considering this association as a separate entity.
  • [MeSH-major] Cystadenoma, Serous / pathology. Endocrine Gland Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Proteins / metabolism. von Hippel-Lindau Disease / metabolism. von Hippel-Lindau Disease / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 2000 Jan;73(865):83-6 [10721327.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1320-7 [10555000.001]
  • [Cites] J Clin Pathol. 2000 Oct;53(10):800-2 [11064680.001]
  • [Cites] J Histochem Cytochem. 2000 Dec;48(12):1667-76 [11101635.001]
  • [Cites] Surgery. 2000 Dec;128(6):1022-7;discussion 1027-8 [11114638.001]
  • [Cites] Arch Surg. 2003 Apr;138(4):427-3; discussion 433-4 [12686529.001]
  • [Cites] Arch Pathol Lab Med. 2003 Oct;127(10):1369-72 [14521452.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1934-8 [15070966.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):339-46 [15104296.001]
  • [Cites] N Engl J Med. 2004 Sep 16;351(12):1218-26 [15371579.001]
  • [Cites] Arch Pathol. 1971 Jul;92(1):28-30 [5091592.001]
  • [Cites] Virchows Arch B Cell Pathol. 1974;17(1):13-27 [4217036.001]
  • [Cites] Ann Surg. 1981 Feb;193(2):185-90 [6258500.001]
  • [Cites] Hum Pathol. 1982 Mar;13(3):263-71 [7076209.001]
  • [Cites] Gastroenterology. 1987 Jun;92(6):1934-43 [3471621.001]
  • [Cites] Am J Surg Pathol. 1988 Apr;12(4):251-63 [3354751.001]
  • [Cites] Am J Surg Pathol. 1989 Jan;13(1):61-6 [2909198.001]
  • [Cites] Ann Surg. 1990 Oct;212(4):432-43; discussion 444-5 [2171441.001]
  • [Cites] Int J Pancreatol. 1991 Oct;10(2):161-72 [1748829.001]
  • [Cites] Cancer. 1992 May 15;69(10):2449-53 [1568167.001]
  • [Cites] Gastroenterol Clin Biol. 1993;17(12):968-71 [8125232.001]
  • [Cites] Virchows Arch. 1994;424(1):13-7 [7526946.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):471-5 [8604814.001]
  • [Cites] J Korean Med Sci. 1997 Oct;12(5):469-72 [9364309.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):223-31 [9665483.001]
  • [Cites] Arch Pathol. 1962 Nov;74:439-52 [13931023.001]
  • [Cites] Ann Diagn Pathol. 2005 Aug;9(4):234-8 [16084460.001]
  • [Cites] Gastroenterology. 2000 Oct;119(4):1087-95 [11040195.001]
  • (PMID = 16644876.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 32
  • [Other-IDs] NLM/ PMC1860571
  •  go-up   go-down


34. Fujarewicz K, Jarzab M, Eszlinger M, Krohn K, Paschke R, Oczko-Wojciechowska M, Wiench M, Kukulska A, Jarzab B, Swierniak A: A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. Endocr Relat Cancer; 2007 Sep;14(3):809-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping.
  • We also assessed the accuracy of benign/malignant classification, based on gene expression profiling, for PTC.
  • We analyzed a 180-array dataset (90 HG-U95A and 90 HG-U133A oligonucleotide arrays), which included a collection of 57 PTCs, 61 benign thyroid tumors, and 62 apparently normal tissues.
  • The accuracy of PTC diagnosis was 98.5% for a 20-gene classifier, its 95% confidence interval (CI) was 95.9-100%, with the lower limit of CI exceeding 95% already for five genes.
  • [MeSH-major] Automatic Data Processing / instrumentation. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / genetics. Molecular Diagnostic Techniques / methods. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Diagnosis, Differential. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genes, Neoplasm. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Endocrinol (Oxf). 2000 Nov;53(5):635-44 [11106926.001]
  • [Cites] Thyroid. 2001 Jan;11(1):41-6 [11272096.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3640-6 [11325833.001]
  • [Cites] J Pathol. 2001 May;194(1):4-8 [11329134.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4583-90 [11389094.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):8961-5 [11470909.001]
  • [Cites] Thyroid. 2001 Aug;11(8):783-7 [11525273.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):875-80 [11556840.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):4834-42 [11600550.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15044-9 [11752453.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):175-83 [11786411.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):143-50 [11789719.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):171-8 [15308542.001]
  • [Cites] Thyroid. 2004 Dec;14(12):1037-46 [15650356.001]
  • [Cites] Radiat Res. 2005 Feb;163(2):172-82 [15658893.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1587-97 [15735049.001]
  • [Cites] Thyroid. 2005 Mar;15(3):210-21 [15785240.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2314-20 [15623817.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):1921-4 [15687333.001]
  • [Cites] Bioinformatics. 2005 Apr 15;21(8):1509-15 [15572470.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1545-52 [15812549.001]
  • [Cites] J Invest Dermatol. 2005 May;124(5):906-13 [15854029.001]
  • [Cites] J Clin Endocrinol Metab. 2005 May;90(5):2512-21 [15713710.001]
  • [Cites] Cancer Lett. 2005 Jun 28;224(2):289-301 [15914279.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):291-303 [15947104.001]
  • [Cites] Surgery. 1999 Dec;126(6):1200-4 [10598208.001]
  • [Cites] Endocrinology. 2000 Apr;141(4):1403-13 [10746644.001]
  • [Cites] Genomics. 2002 Jan;79(1):24-30 [11827454.001]
  • [Cites] Mol Endocrinol. 2002 May;16(5):912-23 [11981027.001]
  • [Cites] Oncogene. 2002 May 2;21(19):2971-80 [12082527.001]
  • [Cites] Endocr J. 2002 Aug;49(4):511-6 [12402984.001]
  • [Cites] J Natl Cancer Inst. 2003 Jan 1;95(1):14-8 [12509396.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jan;88(1):260-9 [12519863.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):68-75 [12538453.001]
  • [Cites] Cytopathology. 2003 Feb;14(1):27-31 [12588307.001]
  • [Cites] J Biol Chem. 2003 Feb 21;278(8):6160-7 [12456677.001]
  • [Cites] Biochemistry. 2003 Apr 22;42(15):4569-77 [12693954.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1792-800 [12738736.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2864-71 [12782592.001]
  • [Cites] Histopathology. 2003 Jun;42(6):580-7 [12786894.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):871-5 [12820316.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6784-90 [14583474.001]
  • [Cites] Hum Pathol. 2003 Nov;34(11):1092-100 [14652809.001]
  • [Cites] Mutat Res. 2003 Dec 10;533(1-2):201-9 [14643421.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8500-6 [14679016.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jan;89(1):272-80 [14715861.001]
  • [Cites] Oncogene. 2004 Jan 22;23(3):795-804 [14737114.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1391-7 [14551144.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):703-6 [15266330.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):425-36; discussion 436-7 [15319714.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3531-9 [15337802.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6586-97 [15475448.001]
  • [Cites] Endocrinology. 2004 Nov;145(11):5397-405 [15271884.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1764-71 [15496625.001]
  • [Cites] Am J Clin Pathol. 1989 Nov;92(5):654-8 [2479256.001]
  • [Cites] Oncogene. 1995 Jan 5;10(1):61-8 [7824279.001]
  • [Cites] J Biol Chem. 1995 Jul 21;270(29):17594-601 [7615566.001]
  • [Cites] J Cell Sci. 1996 Jan;109 ( Pt 1):191-7 [8834803.001]
  • [Cites] Genomics. 1996 Dec 15;38(3):273-6 [8975702.001]
  • [Cites] J Clin Endocrinol Metab. 1997 May;82(5):1638-41 [9141564.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2322-8 [9215314.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jan;83(1):157-64 [9435434.001]
  • [Cites] Eur J Pharmacol. 1998 Jan 12;341(2-3):289-97 [9543251.001]
  • [Cites] Biochem Biophys Res Commun. 1998 May 29;246(3):888-94 [9618307.001]
  • [Cites] Br J Cancer. 1998 Jul;78(2):221-4 [9683297.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2817-23 [9709953.001]
  • [Cites] Genomics. 1998 Aug 1;51(3):445-51 [9721215.001]
  • [Cites] J Biol Chem. 1999 Apr 23;274(17):11742-50 [10206990.001]
  • [Cites] Int J Cancer. 1999 Jun 11;81(6):956-62 [10362145.001]
  • [Cites] Mol Cell Endocrinol. 1999 May 25;151(1-2):103-19 [10411325.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3228-34 [10487692.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4542-5 [10493503.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Dec;89(12):6146-54 [15579771.001]
  • [Cites] Eur J Histochem. 2004 Jul-Sep;48(3):253-9 [15590415.001]
  • [Cites] Exp Oncol. 2004 Dec;26(4):282-6 [15627060.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):48-57 [15272279.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2216-24 [15956966.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4155-61 [15806164.001]
  • [Cites] Mol Endocrinol. 2005 Sep;19(9):2349-57 [15890670.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6646-56 [16007166.001]
  • [Cites] Pathol Int. 2005 Nov;55(11):694-702 [16271081.001]
  • [Cites] Thyroid. 2005 Oct;15(10):1137-46 [16279847.001]
  • [Cites] JAMA. 2006 Jan 4;295(1):81-9 [16391220.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):262-9 [16249278.001]
  • [Cites] Acta Chir Belg. 2005 Nov-Dec;105(6):644-8 [16438077.001]
  • [Cites] J Surg Res. 2006 Mar;131(1):15-25 [16256137.001]
  • [Cites] Am J Clin Pathol. 2006 Mar;125(3):399-406 [16613343.001]
  • [Cites] Biochimie. 2006 Mar-Apr;88(3-4):387-97 [16480812.001]
  • [Cites] BMC Bioinformatics. 2006;7:197 [16606446.001]
  • [Cites] J Clin Endocrinol Metab. 2006 May;91(5):1934-42 [16407496.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2592-7 [16688775.001]
  • [Cites] Thyroid. 2006 Jul;16(7):633-42 [16889486.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Sep;2(9):472-3 [16957755.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5043-51 [17075124.001]
  • [Cites] Endokrynol Pol. 2006;57 Suppl A:12-7 [17091451.001]
  • [Cites] Placenta. 2007 Feb-Mar;28(2-3):77-84 [16584773.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):994-1005 [14764826.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):374-80 [14960464.001]
  • [Cites] Thyroid. 2004 Mar;14(3):169-75 [15072698.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1600-5 [15083192.001]
  • [Cites] Eur J Endocrinol. 2004 Apr;150(4):547-56 [15080786.001]
  • [Cites] J Clin Invest. 2004 Apr;113(8):1234-42 [15085203.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2898-903 [15087409.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3780-9 [15172984.001]
  • [Cites] Biochim Biophys Acta. 2004 Jun 28;1689(2):134-41 [15196594.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3214-23 [15240595.001]
  • [Cites] Histopathology. 2004 Aug;45(2):103-18 [15279628.001]
  • [Cites] Mol Cancer Ther. 2004 Aug;3(8):1011-20 [15299084.001]
  • (PMID = 17914110.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2216417
  •  go-up   go-down


35. Ramuz O, Lelong B, Giovannini M, Delpero JR, Rochaix P, Xerri L, Hassoun J, Flejou JF, Monges G: "Sugar" tumor of the pancreas: a rare entity that is diagnosable on preoperative fine-needle biopsies. Virchows Arch; 2005 May;446(5):555-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Sugar" tumor of the pancreas: a rare entity that is diagnosable on preoperative fine-needle biopsies.
  • This study is the second to report a pancreatic "sugar" tumor (ST) case.
  • This ST was incidentally discovered in a 31-year-old woman using computed tomography scan (CT scan) for work-up of a hepatic focal nodular hyperplasia.
  • Both CT scan and endoluminal ultrasonography (EUS) features evoked a 15-mm large benign endocrine tumor.
  • Pathological examination of EUS-guided fine-needle aspiration biopsies could not confirm this diagnosis.
  • The tumor was intrapancreatic, well circumscribed, and organized in sheets of epithelioid cells.
  • The tumor cells expressed HMB-45 but did not express epithelial or endocrine immunohistochemical markers.
  • This observation highlights that STs should be considered in preoperative differential diagnosis of pancreas tumors, since they may be treated by limited surgical resection.
  • [MeSH-major] Biopsy, Fine-Needle. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Angiomyolipoma / chemistry. Angiomyolipoma / pathology. Angiomyolipoma / surgery. Antigens, Neoplasm. Diagnosis, Differential. Female. Focal Nodular Hyperplasia / complications. Humans. Laparoscopy. Melanoma-Specific Antigens. Neoplasm Proteins / analysis. Pancreatectomy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 1994 Jul;26(3):230-6 [7991275.001]
  • [Cites] Pathologe. 2001 Nov;22(6):417-23 [11766641.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):563-8 [11406657.001]
  • [Cites] Mod Pathol. 2003 May;16(5):481-90 [12748255.001]
  • [Cites] Arch Pathol Lab Med. 1988 Dec;112(12):1177-8 [3190399.001]
  • [Cites] Cancer. 1984 Aug 1;54(3):517-9 [6733682.001]
  • [Cites] Am J Surg Pathol. 2002 May;26(5):670-5 [11979098.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1239-46 [10976698.001]
  • [Cites] Hepatology. 1997 Oct;26(4):891-5 [9328310.001]
  • [Cites] Arch Pathol Lab Med. 2001 Jun;125(6):751-8 [11371226.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):65-70 [11145253.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):223-31 [9665483.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):121-6 [11145246.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):615-22 [11406665.001]
  • [Cites] Hum Pathol. 1998 Oct;29(10):1063-7 [9781642.001]
  • [Cites] Am J Surg Pathol. 1996 Jun;20(6):722-30 [8651352.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):889-94 [10843294.001]
  • [Cites] Pancreas. 2004 May;28(4):443-5 [15097863.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1295-9 [10976706.001]
  • (PMID = 15821930.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


36. Portela-Gomes GM, Grimelius L, Stridsberg M: Immunohistochemical and biochemical studies with region-specific antibodies to chromogranins A and B and secretogranins II and III in neuroendocrine tumors. Cell Mol Neurobiol; 2010 Nov;30(8):1147-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The immunohistochemical expression of different epitopes of the granin family of proteins varies in NE cells in normal human endocrine and non-endocrine organs and in NETs, suggesting post-translational processing.
  • In most NETs one or more epitopes of the granins were lacking, but variations in the expression pattern occurred both in benign and malignant NETs.
  • A few epitopes displayed patterns that may be valuable in differentiating between benign and malignant NET types, e.g., well-differentiated NET types expressed more CgA epitopes than the poorly differentiated ones and C-terminal secretoneurin visualized a cell type related to malignancy in pheochromocytomas.
  • In patients suffering from carcinoid tumors or endocrine pancreatic tumors the highest concentrations were found with epitopes from the mid-portion of CgA.
  • Measurements of SgII showed that patients with endocrine pancreatic tumors had higher concentrations than patients with carcinoid tumors or pheochromocytomas.
  • [MeSH-major] Antibodies, Neoplasm / immunology. Chromogranins / immunology. Neuroendocrine Tumors / immunology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Oct;157(4):1299-309 [11021834.001]
  • [Cites] Regul Pept. 2007 Mar 1;139(1-3):80-3 [17116339.001]
  • [Cites] Cancer. 1991 Feb 1;67(3):663-72 [1702355.001]
  • [Cites] FEBS Lett. 1988 Jul 4;234(1):160-4 [3134253.001]
  • [Cites] Adv Exp Med Biol. 2000;482:193-203 [11192580.001]
  • [Cites] Regul Pept. 2004 Mar 15;117(3):219-27 [14749043.001]
  • [Cites] J Anat. 2008 Mar;212(3):229-34 [18221483.001]
  • [Cites] Endocr Pathol. 2003 Spring;14(1):3-23 [12746559.001]
  • [Cites] J Neurosci. 1990 Sep;10(9):3135-47 [2204688.001]
  • [Cites] Prog Neurobiol. 1995 May;46(1):49-70 [7568909.001]
  • [Cites] Regul Pept. 2005 Feb 15;125(1-3):193-9 [15582732.001]
  • [Cites] Cell Mol Life Sci. 2007 Nov;64(22):2863-86 [17717629.001]
  • [Cites] Adv Pharmacol. 1998;42:257-9 [9327893.001]
  • [Cites] Endocr Pathol. 2003 Spring;14 (1):37-48 [12746561.001]
  • [Cites] Adv Exp Med Biol. 2000;482:319-27 [11192592.001]
  • [Cites] Regul Pept. 2010 Nov 30;165(1):12-20 [20211659.001]
  • [Cites] Diabetes. 1986 Mar;35(3):300-5 [3512340.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):399-406 [16408221.001]
  • [Cites] J Biol Chem. 1996 Nov 8;271(45):28533-40 [8910482.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1261-7 [11688460.001]
  • [Cites] FEBS Lett. 1982 Oct 18;147(2):261-6 [6816630.001]
  • [Cites] Virchows Arch. 2005 Jun;446(6):604-12 [15906087.001]
  • [Cites] J Biol Chem. 1983 Sep 25;258(18):11326-34 [6577005.001]
  • [Cites] J Biol Chem. 1997 Apr 25;272(17):11657-62 [9111083.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1426-30 [1996343.001]
  • [Cites] APMIS. 2004 Oct;112(10):663-73 [15601318.001]
  • [Cites] Am J Surg Pathol. 1988 Nov;12(11):877-84 [2847571.001]
  • [Cites] J Endocrinol. 1995 Jan;144(1):49-59 [7891024.001]
  • [Cites] Ann N Y Acad Sci. 1987;493:120-34 [3296906.001]
  • [Cites] N Engl J Med. 1986 May 1;314(18):1145-51 [3007986.001]
  • [Cites] Regul Pept. 2008 Jun 5;148(1-3):95-8 [18448176.001]
  • [Cites] Biochem J. 1991 Jun 1;276 ( Pt 2):471-9 [1710890.001]
  • [Cites] Mol Cell Endocrinol. 1981 Nov;24(2):181-93 [7297761.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):2003-12 [16287097.001]
  • [Cites] Biol Rev Camb Philos Soc. 2004 Nov;79(4):769-94 [15682870.001]
  • [Cites] Acta Oncol. 2004;43(7):617-25 [15545182.001]
  • [Cites] J Histochem Cytochem. 2002 Aug;50(8):1023-30 [12133905.001]
  • [Cites] Mol Pharmacol. 1966 Jul;2(4):298-310 [5968070.001]
  • [Cites] Am J Surg Pathol. 2002 May;26(5):551-66 [11979086.001]
  • [Cites] J Histochem Cytochem. 2001 Apr;49(4):483-90 [11259451.001]
  • [Cites] Regul Pept. 2010 Nov 30;165(1):30-5 [20550951.001]
  • [Cites] Virchows Arch. 1995;426(4):361-7 [7599788.001]
  • [Cites] Biochem J. 1965 Dec;97(3):40C-41C [5881651.001]
  • [Cites] Regul Pept. 2003 Jun 15;114(1):29-35 [12763637.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Aug;82(16):5300-4 [3875097.001]
  • [Cites] J Histochem Cytochem. 1997 Jun;45(6):815-22 [9199667.001]
  • [Cites] J Pathol. 1999 Feb;187(3):321-5 [10398086.001]
  • (PMID = 21046454.001).
  • [ISSN] 1573-6830
  • [Journal-full-title] Cellular and molecular neurobiology
  • [ISO-abbreviation] Cell. Mol. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Chromogranins
  •  go-up   go-down


37. Matyja E, Maksymowicz M, Grajkowska W, Olszewski W, Zieliński G, Bonicki W: Spindle cell oncocytoma of the adenohypophysis - a clinicopathological and ultrastructural study of two cases. Folia Neuropathol; 2010;48(3):175-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Spindle cell oncocytoma (SCO) of the pituitary gland is a relatively recently established, very rare subtype of adenohypophysis tumours that was introduced as a distinct clinicopathological entity in the fourth edition of WHO classification of the central nervous system tumours (2007).
  • It is non-endocrine neoplasm of the anterior pituitary that occurs in adults and usually follows a benign clinical course, corresponding to WHO grade I.
  • The clinical and radiological features suggested non-functioning pituitary macroadenomas without evidence of invasive growth.
  • One patient presented with tumour recurrence 3 years after undergoing the previous surgical removal of tumour, which was initially misdiagnosed as schwannoma.
  • The first tumour was removed by transsphenoidal surgery and the second one by frontal craniotomy.
  • The tumour cells exhibited immunoreactivity for S-100 protein, galectin-3, vimentin and epithelial membrane antigen but they were negative for GFAP, anterior pituitary neuroendocrine markers (prolactin, growth hormone, TSH, ACTH, FSH, LH), chromogranin, synaptophysin, cytokeratin CK (AE1/AE3), smooth muscle actin, desmin, CD34 and CD68.
  • Ultrastructurally, the tumour cells were rich in mitochondria with lamellar cristae.
  • Moreover, in Case 2 some tumour cells showed a number of giant mitochondria with severely destructed internal matrix.
  • It should be considered in the differential diagnosis of various sellar-region lesions of oncocytic morphology.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20925001.001).
  • [ISSN] 1509-572X
  • [Journal-full-title] Folia neuropathologica
  • [ISO-abbreviation] Folia Neuropathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


38. Gilfillan CP: Review of the genetics of thyroid tumours: diagnostic and prognostic implications. ANZ J Surg; 2010 Jan;80(1-2):33-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite this, the frequency of thyroid cancer is on the increase and thyroid malignancy is the most common endocrine malignancy.
  • Preoperative diagnosis is based on ultrasound and radionucleotide imaging as well as the fine-needle aspiration biopsy (FNAB).
  • These biopsies yield a large proportion of indeterminate results due to inadequate material for cytological diagnosis, or due to the cytological similarity of FAs and follicular carcinomas.
  • This technology has the potential to increase the specificity of this test, combining cytological with genetic testing to reduce the number of indeterminate results, thereby reducing the number of thyroidectomies performed for benign disease.
  • [MeSH-major] Thyroid Neoplasms / genetics. Thyroid Neoplasms / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. DNA, Neoplasm / genetics. Diagnosis, Differential. Humans. Mutation. Neoplastic Syndromes, Hereditary / genetics. Neoplastic Syndromes, Hereditary / pathology. Proto-Oncogenes / genetics. Thyroid Nodule / genetics. Thyroid Nodule / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20575878.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Number-of-references] 61
  •  go-up   go-down


39. Alsharif M, Carlo-Demovich J, Massey C, Madory JE, Lewin D, Medina AM, Recavarren R, Houser PM, Yang J: Telecytopathology for immediate evaluation of fine-needle aspiration specimens. Cancer Cytopathol; 2010 Jun 25;118(3):119-26
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: On-site evaluation of fine-needle aspiration (FNA) specimens by a pathologist is essential to obtain adequate samples and provide a preliminary diagnosis.
  • The authors present their experience with on-site evaluation using telecytopathology.
  • A pathologist accessed the real-time images on a computer and interpreted them while communicating with on-site operators over the telephone.
  • Sample adequacy and accuracy of preliminary diagnosis were compared with those obtained by regular on-site evaluation.
  • RESULTS: A total of 429 telecytopathology cases and 363 conventional on-site cases were compared.
  • Preliminary diagnoses of unsatisfactory, adequate (defer), negative/benign, atypical, neoplasm, suspicious, and positive for malignancy were 6.3%, 13.5%, 14.9%, 17.9%, 7.2%, 8.6%, and 31.5% for telecytopathology and 3.9%, 30.6%, 21.5%, 9.6%, 5.0%, 5.2%, and 24.2% for conventional cases.
  • Difficulty was encountered in some cases in distinguishing pancreatic endocrine neoplasm from lymphoid proliferations, and low grade pancreatic tumors from chronic pancreatitis via telecytopathology.
  • CONCLUSIONS: On-site evaluation of FNA specimens via telecytopathology assures sample adequacy and accurate preliminary diagnosis compared with the conventional method.
  • It allows pathologists to use their time more efficiently and makes on-site evaluations at remote locations possible.
  • [MeSH-major] Biopsy, Fine-Needle. Neoplasms / diagnosis. Telepathology / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Cancer Society.
  • [CommentIn] Cancer Cytopathol. 2010 Jun 25;118(3):115-8 [20544703.001]
  • (PMID = 20544707.001).
  • [ISSN] 1934-662X
  • [Journal-full-title] Cancer cytopathology
  • [ISO-abbreviation] Cancer Cytopathol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Mete O, Rotstein L, Asa SL: Controversies in thyroid pathology: thyroid capsule invasion and extrathyroidal extension. Ann Surg Oncol; 2010 Feb;17(2):386-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION AND DESIGN: Endocrine pathologists, surgeons, and oncologists who manage patients with thyroid carcinomas confront many critical dilemmas.
  • Controversies surrounding diagnostic criteria that distinguish benign from malignant thyroid follicular lesions have been brought to the attention of this community.
  • In this article, we confront another controversy, the definition of a thyroid "capsule" to clarify what constitutes extrathyroidal extension (ETE) and its clinical significance in the management of patients with differentiated thyroid carcinomas.
  • RESULTS AND CONCLUSION: Our review of the anatomy of the thyroid gland confirms that this structure has no defined anatomical fibrous capsule.
  • Moreover, the presence of adipose tissue within the thyroid gland and its pseudocapsule implies that thyroid tumor within fat tissue cannot be accepted as a criterion of ETE by that thyroid carcinoma.
  • While invasion of skeletal muscle is a more reliable feature of ETE, at the isthmus, these fibers can be normally present within the gland, and this criterion does not have value.
  • [MeSH-major] Connective Tissue / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Humans. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Thyroid Gland / anatomy & histology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19949881.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


41. Da Ines D, Petitcolin V, Lannareix V, Montoriol P, Joubert Zakeyh J, Boyer L, Garcier J: [Liver capsule retraction adjacent to a circumscribed liver lesion: review of 26 cases with histological confirmation]. J Radiol; 2009 Sep;90(9 Pt 1):1067-74
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Rétraction capsulaire hépatique en regard d'une lésion circonscrite: à propos de 26 patients avec preuve histologique.
  • PURPOSE: To review the histological features of 26 circumscribed liver lesions associated with liver capsule retraction and discuss the differential diagnosis while evaluating for the presence of fibrous stromal reaction.
  • RESULTS: Twenty-one patients had benign or malignant liver tumors and 5 patients had confluent hepatic fibrosis.
  • Twenty of 21 liver tumors were malignant (95.2%): 3 intra-hepatic cholangiocarcinoma, 17 cases of metastatic disease including colorectal carcinoma (n=8), bronchogenic carcinoma (n=1), pancreatic carcinoma (n=4), esophageal carcinoma (n=1), breast carcinoma (n=1), gallbladder carcinoma (1) and endocrine neoplasm of the pancreas (n=1), and 1 case of liver sclerosing angioma (n=1).
  • CONCLUSION: The presence of capsular retraction next to a circumscribed liver lesion, while non-specific, is suspicious.
  • In keeping with previous reports, metastases were frequently the cause and intrahepatic cholangiocarcinoma was the most frequent primary tumor.
  • [MeSH-major] Liver Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Radiol. 2009 Sep;90(9 Pt 1):1019-20 [19752803.001]
  • (PMID = 19752810.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


42. Korpershoek E, Loonen AJ, Corvers S, van Nederveen FH, Jonkers J, Ma X, Ziel-van der Made A, Korsten H, Trapman J, Dinjens WN, de Krijger RR: Conditional Pten knock-out mice: a model for metastatic phaeochromocytoma. J Pathol; 2009 Mar;217(4):597-604
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phaeochromocytomas (PCCs) are neuro-endocrine tumours of the adrenal medulla that are usually benign, but approximately 10% of patients develop metastases.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Disease Models, Animal. Lung Neoplasms / secondary. Neoplasm Proteins / genetics. PTEN Phosphohydrolase / genetics. Pheochromocytoma / secondary


43. Adler JT, Meyer-Rochow GY, Chen H, Benn DE, Robinson BG, Sippel RS, Sidhu SB: Pheochromocytoma: current approaches and future directions. Oncologist; 2008 Jul;13(7):779-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Improved medical management and surgical techniques and an increased understanding of hereditary disease have improved the outcome of pheochromocytoma patients with benign disease; however, the outcome of patients with malignant disease remains poor.
  • In this review, we discuss the presentation, diagnosis, management, and future directions in the management of this disease.
  • [MeSH-major] Adrenal Gland Neoplasms. Pheochromocytoma
  • [MeSH-minor] Adrenal Glands / surgery. Chemotherapy, Adjuvant. Genetic Predisposition to Disease. Humans. Neoplasm Metastasis / prevention & control. Radiotherapy, Adjuvant


44. Vagefi PA, Razo O, Deshpande V, McGrath DJ, Lauwers GY, Thayer SP, Warshaw AL, Fernández-Del Castillo C: Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. Arch Surg; 2007 Apr;142(4):347-54
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005.
  • OBJECTIVE: To assess changing patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms (PNENs).
  • Insulinomas were the most common type of functional neoplasm (33.3%), followed by gastrinomas and glucagonomas; 12 patients (7.1%) had multiple endocrine neoplasia type 1.
  • Of the neoplasms, 107 (63.7%) were located in the pancreatic body or tail.
  • We classified 76.8% of neoplasms as benign; of those classified as malignant, 25.6% had liver metastases.
  • Incidentally discovered nonfunctioning neoplasms were significantly more frequent in the last 5 years (60.4% vs 40.3%; P = .007), with a trend toward smaller neoplasms (mean, 4.2 cm vs 5.6 cm; P = .19) and lesser likelihood of malignancy (21.8% vs 40.0%; P = .08).
  • Increasing numbers of PNENs are being resected, largely owing to the incidental detection of nonfunctioning neoplasms.
  • This may lead to the treatment of smaller and less malignant neoplasms.
  • [MeSH-major] Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Diagnosis, Differential. Female. Follow-Up Studies. Hospitals, General. Humans. Male. Massachusetts / epidemiology. Middle Aged. Retrospective Studies. Survival Rate / trends. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 2006 Aug;141(8):765-9; discussion 769-70 [16924083.001]
  • [Cites] JSLS. 2006 Apr-Jun;10(2):259-62 [16882434.001]
  • [Cites] Surgery. 2001 Dec;130(6):1078-85 [11742342.001]
  • [Cites] Arch Surg. 2003 Apr;138(4):427-3; discussion 433-4 [12686529.001]
  • [Cites] Am J Gastroenterol. 2003 Nov;98(11):2435-9 [14638345.001]
  • [Cites] Can J Surg. 2003 Dec;46(6):413-8 [14680347.001]
  • [Cites] J Am Coll Surg. 2004 May;198(5):722-31 [15110805.001]
  • [Cites] J Surg Res. 2004 Jul;120(1):139-61 [15172200.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1145-53 [15316313.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6919-28 [15501970.001]
  • [Cites] Ann Intern Med. 1973 Jul;79(1):101-7 [4352783.001]
  • [Cites] Ann Surg. 1981 Feb;193(2):185-90 [6258500.001]
  • [Cites] Gastroenterology. 1995 Jun;108(6):1637-49 [7768367.001]
  • [Cites] Arch Surg. 1998 Mar;133(3):327-31 [9517749.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):429-38 [9742926.001]
  • [Cites] J Gastrointest Surg. 1998 Sep-Oct;2(5):472-82 [9843608.001]
  • [Cites] Mayo Clin Proc. 1999 Jul;74(7):735-8 [10405707.001]
  • [Cites] Surgery. 2005 Jun;137(6):597-605 [15962401.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):781-8, discussion 788-90 [16327488.001]
  • [Cites] J Gastrointest Surg. 2006 Mar;10(3):324-6 [16622982.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):391-8 [11296108.001]
  • (PMID = 17438169.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK071329; United States / NCI NIH HHS / CA / P01 CA117969
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS519098; NLM/ PMC3979851
  •  go-up   go-down


45. Kars M, Roelfsema F, Romijn JA, Pereira AM: Malignant prolactinoma: case report and review of the literature. Eur J Endocrinol; 2006 Oct;155(4):523-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In general, the initial clinical, biochemical, and histological characteristics are of minimal utility in distinguishing benign adenomas from pituitary carcinomas.
  • In brief, it is postulated that pituitary carcinomas arise from the transformation of initially large, but benign, adenomas.
  • In vivo, the development of dopamine agonist resistance in invasive macroprolactinoma is indicative of malignancy and should prompt the clinician to perform a biopsy of the tumor.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990651.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Pyrrolidines; 107188-87-4 / epidepride; 9002-62-4 / Prolactin
  • [Number-of-references] 47
  •  go-up   go-down


46. Fritzsche S, Kenzelmann M, Hoffmann MJ, Müller M, Engers R, Gröne HJ, Schulz WA: Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma. Endocr Relat Cancer; 2006 Sep;13(3):839-49
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found both genes modestly down-regulated by microarray expression analysis of microdissected prostate cancers and by quantitative RT-PCR in macrodissected specimens compared with benign tissues.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Membrane Proteins / genetics. Phosphoproteins / genetics. Prostatic Neoplasms / genetics. Proteins / genetics
  • [MeSH-minor] Cell Line, Tumor. DNA Primers. Gene Amplification. Humans. Intracellular Signaling Peptides and Proteins. Male. Oligonucleotide Array Sequence Analysis. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16954433.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / Phosphoproteins; 0 / Proteins; 0 / RNA, Neoplasm; 0 / SPRY1 protein, human; 0 / SPRY2 protein, human
  •  go-up   go-down


47. Di Cristofaro J, Silvy M, Lanteaume A, Marcy M, Carayon P, De Micco C: Expression of tpo mRNA in thyroid tumors: quantitative PCR analysis and correlation with alterations of ret, Braf , ras and pax8 genes. Endocr Relat Cancer; 2006 Jun;13(2):485-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed a qualitative PCR (Q-PCR) analysis to measure the expression of variants of tpo mRNA in 13 normal tissue samples, 30 benign tumors (BT), 21 follicular carcinomas (FC), 20 classical papillary carcinomas (PCc), 12 follicular variants of papillary carcinomas (PCfv) and nine oncocytic carcinomas (OC).
  • [MeSH-major] Carcinoma / enzymology. Gene Expression Regulation, Neoplastic. Genes, Neoplasm / genetics. Iodide Peroxidase / genetics. Thyroid Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16728576.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors; 0 / RNA, Messenger; EC 1.11.1.8 / Iodide Peroxidase; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


48. Pinchot SN, Al-Wagih H, Schaefer S, Sippel R, Chen H: Accuracy of fine-needle aspiration biopsy for predicting neoplasm or carcinoma in thyroid nodules 4 cm or larger. Arch Surg; 2009 Jul;144(7):649-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of fine-needle aspiration biopsy for predicting neoplasm or carcinoma in thyroid nodules 4 cm or larger.
  • The FNAB results were reported as nondiagnostic, benign, inconclusive (follicular neoplasm), or malignant, whereas the final surgical pathologic data were reported as benign or malignant.
  • Preoperative cytologic testing of the mass was performed on 97 patients, and the results read as benign for 52, inconclusive for 23, nondiagnostic for 11, and malignant for 11.
  • In lesions 4 cm or larger, 26 of 52 FNAB results reported as benign (50.0%) turned out to be either neoplastic (22) or malignant (4) on final pathologic analysis.
  • Among patients with nondiagnostic FNAB results, the risk of malignant neoplasms was 27.3%.
  • CONCLUSIONS: In patients with thyroid nodules 4 cm or larger, the FNAB results are highly inaccurate, misclassifying half of all patients with reportedly benign lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Control. 2006 Apr;13(2):89-98 [16735982.001]
  • [Cites] Ann Surg Oncol. 2006 Jun;13(6):859-63 [16614881.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Oct;65(4):500-5 [16984243.001]
  • [Cites] Ann Surg. 2007 Nov;246(5):714-20 [17968160.001]
  • [Cites] Surgery. 2007 Dec;142(6):837-44; discussion 844.e1-3 [18063065.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Mar;93(3):809-14 [18160464.001]
  • [Cites] Surgery. 2008 Jun;143(6):835-6 [18549905.001]
  • [Cites] Otolaryngol Head Neck Surg. 2008 Jul;139(1):27-31 [18585557.001]
  • [Cites] Ann Surg. 2008 Aug;248(2):343-4; author reply 344 [18650649.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Jun;122(6):917-21 [10828810.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1764-71 [15496625.001]
  • [Cites] Surgery. 1988 Dec;104(6):947-53 [3194846.001]
  • [Cites] Acta Endocrinol (Copenh). 1989 Aug;121(2):197-202 [2773619.001]
  • [Cites] Radiology. 1991 Dec;181(3):683-7 [1947082.001]
  • [Cites] J Surg Oncol. 1992 Aug;50(4):247-50 [1640709.001]
  • [Cites] Ann Intern Med. 1993 Feb 15;118(4):282-9 [8420446.001]
  • [Cites] Cancer. 1993 Nov 1;72(9):2680-5 [8402490.001]
  • [Cites] Surgery. 1993 Dec;114(6):1050-7; discussion 1057-8 [8256208.001]
  • [Cites] Arch Intern Med. 1994 Aug 22;154(16):1838-40 [8053752.001]
  • [Cites] Surgery. 1995 Dec;118(6):996-1003; discussion 1003-4 [7491545.001]
  • [Cites] Mayo Clin Proc. 1997 Oct;72(10):913-6 [9379692.001]
  • [Cites] J Clin Endocrinol Metab. 1955 Oct;15(10):1270-80 [13263417.001]
  • [Cites] Thyroid. 2005 Jul;15(7):708-17 [16053388.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Sep;91(9):3411-7 [16835280.001]
  • (PMID = 19620545.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090217-08; United States / NCI NIH HHS / CA / T32 CA090217-09; United States / NCI NIH HHS / CA / T32 CA090217-10; United States / NCI NIH HHS / CA / T32 CA090217; United States / NCI NIH HHS / CA / CA090217-10; United States / NCI NIH HHS / CA / T32 CA090217-08; United States / NCI NIH HHS / CA / CA090217-09
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS215984; NLM/ PMC2910711
  •  go-up   go-down


49. Kyrönlahti A, Kauppinen M, Lind E, Unkila-Kallio L, Butzow R, Klefström J, Wilson DB, Anttonen M, Heikinheimo M: GATA4 protects granulosa cell tumors from TRAIL-induced apoptosis. Endocr Relat Cancer; 2010 Sep;17(3):709-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent cytokine that induces apoptosis in a variety of malignancies without toxic effects on benign cells.
  • [MeSH-major] Apoptosis. GATA4 Transcription Factor / metabolism. Granulosa Cell Tumor / metabolism. Granulosa Cell Tumor / pathology. Neoplasm Recurrence, Local / metabolism. TNF-Related Apoptosis-Inducing Ligand / metabolism
  • [MeSH-minor] Cell Line, Tumor. Female. Granulosa Cells / metabolism. Granulosa Cells / pathology. Humans. Immunoenzyme Techniques. Receptors, TNF-Related Apoptosis-Inducing Ligand / metabolism. Receptors, Tumor Necrosis Factor / metabolism. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20554787.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GATA4 Transcription Factor; 0 / GATA4 protein, human; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFRSF10A protein, human
  •  go-up   go-down


50. Raffel A, Eisenberger CF, Cupisti K, Schott M, Baldus SE, Hoffmann I, Aydin F, Knoefel WT, Stoecklein NH: Increased EpCAM expression in malignant insulinoma: potential clinical implications. Eur J Endocrinol; 2010 Feb;162(2):391-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: EpCAM (CD326) is overexpressed in progenitor cells of endocrine pancreatic islands of Langerhans during fetal development and was suggested to act as a morphoregulatory molecule in pancreatic island ontogeny.
  • We tested whether EpCAM overexpression is reactivated in insulinomas, endocrine tumors arising in the pancreas.
  • DESIGN/METHOD: We used monoclonal anti-EpCAM antibody Ber-Ep4 for immunohistochemistry on formalin-fixed and paraffin-embedded tumor material.
  • We analyzed 53 insulinomas: 40 benign (disease stage<IIa) and 13 malignant tumors (disease stage IIIb/IV).
  • Disease stage disposition followed new TNM classification of the European Neuroendocrine Tumor Society (ENETS) for foregut neuroendocrine tumors (2006).
  • RESULTS: In 38% of the benign insulinomas (disease stage<IIa), we found strong (3+) EpCAM expression.
  • CONCLUSION: This first EpCAM expression study in benign/malignant insulinomas indicates that strong EpCAM expression could help to identify patients at risk for malignant disease and might be used as a therapeutic target for antibody-based therapies in patients with metastatic insulinoma.

  • Genetic Alliance. consumer health - Insulinoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20097833.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / RNA, Messenger
  •  go-up   go-down


51. Jabiev AA, Ikeda MH, Reis IM, Solorzano CC, Lew JI: Surgeon-performed ultrasound can predict differentiated thyroid cancer in patients with solitary thyroid nodules. Ann Surg Oncol; 2009 Nov;16(11):3140-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients were subdivided into two groups based on final pathology results: patients with DTC(n=61) and those with benign disease (BD) (n=54).
  • [MeSH-major] Carcinoma, Papillary, Follicular / ultrasonography. Thyroid Neoplasms / ultrasonography. Thyroid Nodule / ultrasonography
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2011 Dec;18 Suppl 3:S301 [20839063.001]
  • [CommentIn] Ann Surg Oncol. 2011 Jan;18(1):292 [20490696.001]
  • (PMID = 19655201.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Mofid AR, Yazdani T, Shahrzad M, Seyedalinaghi S, Zandieh S: Role of fine-needle aspiration in the management of thyroid nodules. Saudi Med J; 2009 Apr;30(4):515-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: As a retrospective study, reports of 888 FNABs of the thyroid performed during a period of 11 years (1996-2007) at Tehran University of Medical Sciences, Sina Hospital and Endocrine Clinic, Tehran, Iran were reviewed.
  • RESULTS: The cytology diagnoses by FNAB were: papillary 6 (3.2%); follicular neoplasm 51 (28%); follicular adenoma 10 (5.4%); Hurthle cell neoplasm 8 (4.3%); suspicious 20 (10.9%); inconclusive 2 (1%); and benign 85 (46.4%).
  • Due to surgery pathologic reports, malignant cytologies were: 6 (100%) for papillary, 1 (1.96%) for follicular neoplasm, 4 (50%) for Hurthle cell neoplasm.
  • [MeSH-major] Goiter, Nodular / pathology. Thyroid Neoplasms / pathology. Thyroid Nodule / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19370278.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


53. Weismann D, Briese J, Niemann J, Grüneberger M, Adam P, Hahner S, Johanssen S, Liu W, Ezzat S, Saeger W, Bamberger AM, Fassnacht M, Schulte HM, Asa SL, Allolio B, Bamberger CM: Osteopontin stimulates invasion of NCI-h295 cells but is not associated with survival in adrenocortical carcinoma. J Pathol; 2009 Jun;218(2):232-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we demonstrated OPN and integrin alphavbeta3 expression in normal adrenal glands and benign adenomas, with staining seen exclusively in adrenocortical cells as well as even stronger staining in ACC.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / metabolism. Osteopontin / analysis
  • [MeSH-minor] Adenoma / chemistry. Adrenal Glands / chemistry. Blotting, Western / methods. Cell Line, Tumor. Gene Expression Profiling. Humans. Immunohistochemistry. Integrin alphaVbeta3 / analysis. Integrin alphaVbeta3 / genetics. Integrin alphaVbeta3 / metabolism. Kaplan-Meier Estimate. Neoplasm Invasiveness. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction. Statistics, Nonparametric. Transfection / methods

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19326399.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Integrin alphaVbeta3; 106441-73-0 / Osteopontin
  •  go-up   go-down


54. Bhandari T, Dizon DS, Taneja C, Gass J, Masko GD, Strenger R: Clinical characteristics of women presenting with skin-only recurrence of breast cancer. Am J Surg; 2007 Oct;194(4):494-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, locoregional recurrence may have different presentations, some of which may represent a more benign course.
  • Histologic and treatment data as it related to their primary diagnosis and demographic data were obtained by chart review.
  • The median age at original diagnosis was 61 years (range 33-94 years).
  • Ten patients went on to receive endocrine therapy, 6 received chemotherapy, and 2 were observed.
  • CONCLUSIONS: Patients experiencing a chest wall recurrence may have a benign course suggesting this may be an indolent presentation of local regional recurrence.
  • [MeSH-major] Breast Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Neoplasms, Second Primary / therapy. Skin Neoplasms / therapy. Thoracic Wall
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Thoracic Neoplasms

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17826063.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Brauckhoff M, Dralle H: [Recurrent operations on the adrenal glands]. Chirurg; 2005 Mar;76(3):227-37
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrent operations on the adrenal glands].
  • Repeat adrenalectomy may be required due to ipsilateral recurrence of benign or malignant adrenal tumors after previous total or subtotal adrenalectomy.
  • Even for multivisceral resection in patients with adrenocortical carcinoma, complete resection of local recurrent tumor offers results similar to those of primary resection (5-year survival 40-60%).
  • In contrast, since no benefit on long-term survival has been shown so far by tumor debulking, palliative tumor resection should only be performed individually for control of severe endocrine symptoms.
  • In any case, during open or endoscopic approach, tumor spillage must be avoided to prevent local tumor cell implantation.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Adrenocortical Carcinoma / surgery. Neoplasm Recurrence, Local / surgery. Pheochromocytoma / surgery
  • [MeSH-minor] 3-Iodobenzylguanidine / therapeutic use. Adult. Antineoplastic Agents, Hormonal / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymph Node Excision. Male. Middle Aged. Mitotane / therapeutic use. Octreotide / therapeutic use. Palliative Care. Paraneoplastic Endocrine Syndromes / diagnosis. Paraneoplastic Endocrine Syndromes / mortality. Paraneoplastic Endocrine Syndromes / surgery. Radiotherapy, Adjuvant. Reoperation

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endourol. 1999 Mar;13(2):99-104; discussion 104-6 [10213103.001]
  • [Cites] Arch Surg. 2001 May;136(5):543-9 [11343545.001]
  • [Cites] Surgery. 2001 Dec;130(6):1072-7 [11742341.001]
  • [Cites] Ann Thorac Surg. 1996 Jan;61(1):222-4 [8561564.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1043-7 [12045859.001]
  • [Cites] Eur J Surg. 1999 May;165(5):431-5 [10391158.001]
  • [Cites] World J Surg. 1990 May-Jun;14(3):325-9 [1973322.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1347-52 [11038205.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1323-9 [15517476.001]
  • [Cites] World J Surg. 2000 Jan;24(1):108-13 [10594213.001]
  • [Cites] Surgery. 1992 Dec;112(6):963-70; discussion 970-1 [1455321.001]
  • [Cites] Eur J Endocrinol. 2004 Jun;150(6):789-92 [15191348.001]
  • [Cites] Surgery. 2003 Dec;134(6):1020-7; discussion 1027-8 [14668736.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1005-12 [12045858.001]
  • [Cites] World J Surg. 1998 Jun;22(6):621-6; discussion 626-7 [9597938.001]
  • [Cites] N Engl J Med. 1977 Jun 2;296(22):1269-71 [859517.001]
  • [Cites] Endocr J. 2002 Apr;49(2):227-9 [12081243.001]
  • [Cites] Surgery. 1995 Dec;118(6):1090-8 [7491528.001]
  • [Cites] Urology. 1999 Apr;53(4):679-83 [10197840.001]
  • [Cites] Horm Res. 2002;57(5-6):197-9 [12053093.001]
  • [Cites] World J Surg. 2001 Jul;25(7):914-26 [11572033.001]
  • [Cites] Surg Today. 2004;34(3):251-5 [14999539.001]
  • [Cites] Surgery. 1985 Jan;97(1):16-20 [3966225.001]
  • [Cites] Surgery. 2000 Dec;128(6):1007-11;discussion 1011-2 [11114636.001]
  • [Cites] Endocr Rev. 2001 Feb;22(1):75-110 [11159817.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):719-26 [10622498.001]
  • [Cites] Chirurg. 2003 May;74(5):473-7 [12748796.001]
  • [Cites] World J Surg. 1990 May-Jun;14(3):330-4 [2368435.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):5-7 [10634355.001]
  • [Cites] J Am Coll Surg. 2004 Apr;198(4):525-34; discussion 534-5 [15051000.001]
  • [Cites] J Pediatr Surg. 1993 Oct;28(10):1248-51; discussion 1251-2 [8263682.001]
  • [Cites] J Intern Med. 1995 Oct;238(4):363-7 [7595173.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Nov;69(5):1078-81 [2793991.001]
  • [Cites] Eur J Surg. 1999 Jun;165(6):535-8 [10433135.001]
  • [Cites] Surgery. 2003 Dec;134(6):956-62; discussion 962-3 [14668728.001]
  • [Cites] Surgery. 1996 Dec;120(6):1064-70; discussion 1070-1 [8957496.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Jan;46(1):39-44 [9059556.001]
  • [Cites] World J Surg. 1992 Jul-Aug;16(4):753-8 [1413845.001]
  • [Cites] Surgery. 2002 Dec;132(6):1008-11; discussion 1012 [12490848.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2004 Aug;14(4):234-5 [15345163.001]
  • [Cites] J Urol. 1997 Jun;157(6):2239 [9146626.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Dec;87(12):5367-84 [12466322.001]
  • [Cites] J Urol. 1999 Feb;161(2):395-8 [9915410.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4083-7 [12970267.001]
  • [Cites] J Urol. 2000 Jul;164(1):14-7 [10840414.001]
  • [Cites] Arch Surg. 2002 Jun;137(6):682-8; discussion 688-9 [12049539.001]
  • [Cites] World J Surg. 1982 Jul;6(4):397-402 [7123976.001]
  • [Cites] World J Surg. 1984 Aug;8(4):612-21 [6148811.001]
  • [Cites] Surgery. 1997 Dec;122(6):1068-73; discussion 1073-4 [9426421.001]
  • [Cites] ANZ J Surg. 2003 Aug;73(8):664-6 [12887546.001]
  • [Cites] Horm Res. 1999;52(2):97-100 [10681640.001]
  • [Cites] Eur Urol. 2000 Sep;38(3):344-8 [10940711.001]
  • [Cites] Minn Med. 1974 Dec;57(12):951-2 [4424014.001]
  • [Cites] Eur J Endocrinol. 2004 Jul;151(1):15-27 [15248818.001]
  • [Cites] J Endourol. 2002 Apr;16(3):171-4 [12028627.001]
  • [Cites] Chirurg. 1989 Apr;60(4):266-71; discussion 271-2 [2566455.001]
  • [Cites] Arch Surg. 1974 Apr;108(4):450-4 [4815920.001]
  • [Cites] Front Horm Res. 2004;31:155-62 [14674310.001]
  • [Cites] Surgery. 1997 Dec;122(6):1212-8 [9426440.001]
  • [Cites] Br J Surg. 1999 Jan;86(1):94-7 [10027369.001]
  • [Cites] J Urol. 1998 Aug;160(2):330-4 [9679871.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Mar;60(3):273-87 [15008991.001]
  • [Cites] Surgery. 1983 Dec;94(6):938-40 [6648808.001]
  • [Cites] Henry Ford Hosp Med J. 1987;35(2-3):127-8 [2891644.001]
  • (PMID = 15739057.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 35MRW7B4AD / 3-Iodobenzylguanidine; 78E4J5IB5J / Mitotane; RWM8CCW8GP / Octreotide
  • [Number-of-references] 45
  •  go-up   go-down


56. Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, Panzuto F, Pederzoli P, delle Fave G, Falconi M: Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol; 2010 Jun;23(6):824-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients.
  • Pancreatic endocrine tumors are rare diseases and devising a clinically effective prognostic stratification of patients is a major clinical challenge.
  • This study aimed at assessing whether the tumor-node-metastasis (TNM)-based staging and proliferative activity-based grading recently proposed by the European NeuroEndocrine Tumors Society (ENETS) have clinical value.
  • TNM was applied to 274 patients with histologically diagnosed pancreatic endocrine tumors operated from 1991 to 2005, with last follow-up at December 2007.
  • According to World Health Organization (WHO) classification, 246 were well-differentiated neoplasms (51 benign, 56 uncertain behavior, 139 carcinomas) and 28 poorly differentiated carcinomas.
  • Survival analysis not only ascertained the prognostic value of the TNM system but also highlighted that in the absence of nodal and distant metastasis, infiltration and tumor dimensions over 4 cm had prognostic significance.
  • In conclusion, WHO classification assigns clinically significant diagnostic categories to pancreatic endocrine tumors that need prognostic stratification by applying a staging system.
  • The modified TNM described in this study ameliorates the clinical applicability and prediction of outcome of the ENETS-TNM; it (i) assigns a risk of death proportional to the stage at the time of diagnosis, and (ii) allows a clinically based staging of patients, as the T parameters as modified permit their clinical-radiological recognition.
  • [MeSH-major] Carcinoma / diagnosis. Cell Proliferation. Ki-67 Antigen / analysis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Cell Differentiation. Chi-Square Distribution. Female. Humans. Immunohistochemistry. Italy. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Prospective Studies. Risk Assessment. Risk Factors. Time Factors. World Health Organization


57. Morari EC, Silva JR, Guilhen AC, Cunha LL, Marcello MA, Soares FA, Vassallo J, Ward LS: Muc-1 expression may help characterize thyroid nodules but does not predict patients' outcome. Endocr Pathol; 2010 Dec;21(4):242-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our purpose was to evaluate MUC1 clinical utility in the diagnosis and prognosis of thyroid cancer patients.
  • MUC1 distinguished benign from malignant thyroid tissues (sensitivity = 89%; specificity = 53%).
  • q-PCR mRNA expression of MUC1 also distinguished malignant from benign nodules (Mann-Whitney test, p < 0.0001).
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Carcinoma, Papillary / diagnosis. Mucin-1 / biosynthesis. Thyroid Neoplasms / diagnosis. Thyroid Nodule / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Child. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2003;38(12):1162-6 [14714254.001]
  • [Cites] Thyroid. 1997 Oct;7(5):725-31 [9349575.001]
  • [Cites] Thyroid. 2010 May;20(5):465-73 [20384488.001]
  • [Cites] Surgery. 2010 Sep;148(3):532-7 [20236675.001]
  • [Cites] Gastroenterology. 1994 Feb;106(2):353-61 [7905449.001]
  • [Cites] Cancer Cytopathol. 2010 Feb 25;118(1):17-23 [20099311.001]
  • [Cites] Hum Pathol. 1997 Sep;28(9):1056-65 [9308730.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15044-9 [11752453.001]
  • [Cites] Laryngoscope. 2007 May;117(5):911-6 [17473695.001]
  • [Cites] Int J Cancer. 1996 Mar 28;66(1):55-9 [8608966.001]
  • [Cites] Thyroid. 2009 Nov;19(11):1167-214 [19860577.001]
  • [Cites] Laryngoscope. 2008 Apr;118(4):692-6 [18094649.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1447-63 [11297567.001]
  • [Cites] Thyroid. 2004 Feb;14(2):99-111 [15068624.001]
  • [Cites] World J Surg. 2010 Jan;34(1):28-35 [20020290.001]
  • [Cites] Int J Biol Markers. 2000 Oct-Dec;15(4):343-56 [11192832.001]
  • [Cites] Int J Cancer. 1999 Jun 21;84(3):251-7 [10371342.001]
  • [Cites] Endocr Pathol. 2007 Summer;18(2):68-75 [17916995.001]
  • [Cites] Mod Pathol. 2008 Jun;21(6):748-55 [18360353.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):25-34 [15215159.001]
  • [Cites] Biol Pharm Bull. 2008 Dec;31(12):2288-93 [19043215.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2009 Feb 17;89(6):393-6 [19567117.001]
  • [Cites] Mol Cell Endocrinol. 2010 Jun 30;322(1-2):8-28 [20138116.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3780-9 [15172984.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1821-7 [14996745.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):1973-82 [11391575.001]
  • [Cites] Mol Cell Endocrinol. 2010 May 28;321(1):86-93 [19883729.001]
  • (PMID = 21057891.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / RNA, Messenger
  •  go-up   go-down


58. Crippa S, Boninsegna L, Partelli S, Falconi M: Parenchyma-sparing resections for pancreatic neoplasms. J Hepatobiliary Pancreat Sci; 2010 Nov;17(6):782-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parenchyma-sparing resections for pancreatic neoplasms.
  • BACKGROUND/PURPOSE: In recent years there has been an increase in the indications for pancreatic resection of benign or low-grade malignant lesions, especially in young patients with long life expectancy.
  • In this setting, patients may benefit from parenchyma-sparing resections in order to decrease the risk of development of exocrine/endocrine insufficiency.
  • CONCLUSIONS: Parenchyma-sparing resections are safe and effective procedures for treatment of benign and low-grade malignant neoplasms.
  • [MeSH-major] Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Humans. Laparoscopy. Neoplasm Recurrence, Local. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Hepatobiliary Pancreat Sci. 2010 Mar;17(2):203 [20454911.001]
  • (PMID = 19865792.001).
  • [ISSN] 1868-6982
  • [Journal-full-title] Journal of hepato-biliary-pancreatic sciences
  • [ISO-abbreviation] J Hepatobiliary Pancreat Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  •  go-up   go-down


59. Wada I, Shimizu N, Seto Y: [Treatment of neuroendocrine tumors of the digestive tract]. Gan To Kagaku Ryoho; 2009 Oct;36(10):1606-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroendocrine tumors of the digestive tract are relatively rare and comprise benign and malignant tumors.
  • European Neuroendocrine Tumor Society(ENETS)proposed grading system and TNM classification system with disease staging for endocrine tumors of each organ which are both valid tools for prognostic stratification.
  • The only curative therapy is the complete resection of the tumor.
  • Octreotide and Pasireotide (SOM230), somatostatin analogues, are reported to have the benefit of both hormonal symptom control and tumor growth suppression.
  • [MeSH-major] Antinematodal Agents / therapeutic use. Digestive System Neoplasms / drug therapy. Neuroendocrine Tumors / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838017.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antinematodal Agents
  •  go-up   go-down


60. Papi G, Rossi G, Corsello SM, Corrado S, Fadda G, Di Donato C, Pontecorvi A: Nodular disease and parafollicular C-cell distribution: results from a prospective and retrospective clinico-pathological study on the thyroid isthmus. Eur J Endocrinol; 2010 Jan;162(1):137-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The isthmus represents a peculiar, as yet partially unexplored, thyroid gland area.
  • ii) the frequency of medullary thyroid carcinoma (MTC) arising from the isthmus; and iii) the C-cell distribution in the isthmus of patients with MTC and benign nodular thyroid disease (NTD).
  • Immunohistochemistry was performed using anti-C(t) antibodies on lateral lobes and isthmi of 50 benign NTD and 50 MTC cases.
  • All patients had the neoplasm located in lateral thyroid lobes, none in the isthmus.
  • C cells were disclosed in lateral thyroid lobes of 100% MTC and 77% benign NTD patients; isthmi were free of C cells in either group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19793761.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


61. Tena-Suck ML, Ortiz-Plata A, Galán F, Sánchez A: Expression of epithelial cell adhesion molecule and pituitary tumor transforming gene in adamantinomatous craniopharyngioma and its correlation with recurrence of the tumor. Ann Diagn Pathol; 2009 Apr;13(2):82-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of epithelial cell adhesion molecule and pituitary tumor transforming gene in adamantinomatous craniopharyngioma and its correlation with recurrence of the tumor.
  • Craniopharyngiomas are benign tumors of the sellar region generally associated with endocrine disorders and often locally aggressive.
  • The reliable criteria for predicting the tumor behavior are still lacking.
  • It has been suggested that proliferative potential of the tumor cells is necessary for recurrence.
  • The aim of this study was to evaluate the activity and correlation of epithelial cell adhesion molecule (Ep-CAM) and pituitary tumor transforming gene (PTTG-1) immunoexpression that is possibly related to relapse in 40 patients with adamantinomatous craniopharyngioma.
  • The Ep-CAM and PTTG-1 expression in craniopharyngioma could be used as prediction markers of relapsing tumor.
  • It has been suggested that proliferative potential of the tumor cells is necessary for recurrence.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Cell Adhesion Molecules / biosynthesis. Craniopharyngioma / metabolism. Neoplasm Proteins / biosynthesis. Neoplasm Recurrence, Local / metabolism. Pituitary Neoplasms / metabolism
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Female. Gene Expression. Humans. Immunohistochemistry. Male. Securin

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Diagn Pathol. 2009 Dec;13(6):428-9 [19917481.001]
  • (PMID = 19302955.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Neoplasm Proteins; 0 / Securin; 0 / pituitary tumor-transforming protein 1, human
  •  go-up   go-down


62. Basturk O, Coban I, Adsay NV: Pancreatic cysts: pathologic classification, differential diagnosis, and clinical implications. Arch Pathol Lab Med; 2009 Mar;133(3):423-38
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic cysts: pathologic classification, differential diagnosis, and clinical implications.
  • OBJECTIVE: To provide an overview of the current concepts in classification, differential diagnosis, and clinical/biologic behavior of pancreatic cystic tumors.
  • CONCLUSIONS: In contrast to solid tumors, most of which are invasive ductal adenocarcinomas with dismal prognosis, cystic lesions of the pancreas are often either benign or low-grade indolent neoplasia.
  • However, those that are mucinous, namely, intraductal papillary mucinous neoplasms and mucinous cystic neoplasms, constitute an important category because they have well-established malignant potential, representing an adenoma-carcinoma sequence.
  • Only rare nonmucinous cystic tumors that occur as a result of degenerative/necrotic changes in otherwise solid neoplasia, such as cystic ductal adenocarcinomas, cystic pancreatic endocrine neoplasia, and solid-pseudopapillary neoplasm, are also malignant and have variable degrees of aggressiveness.
  • [MeSH-major] Pancreatic Cyst / diagnosis. Pancreatic Cyst / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology. Pancreatic Pseudocyst / diagnosis. Pancreatic Pseudocyst / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260748.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 204
  •  go-up   go-down


63. Buchfelder M, Kann PH, Wüster C, Tuschy U, Saller B, Brabant G, Kleindienst A, Nomikos P, German KIMS Board: Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas: a case control study. Eur J Endocrinol; 2007 Aug;157(2):149-56
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Several studies documented metabolic and psychological benefits of GH substitution in deficient adults, most of them suffering from benign pituitary adenomas.
  • Since GH substitution is considered to promote tumour regrowth, adequate treatment is performed with some reservation.
  • Therefore, we aimed to elucidate the effect of GH replacement therapy on tumour recurrence following surgery.
  • METHODS: In patients with hormonally inactive pituitary adenomas undergoing tumour surgery, a retrospective case-control study was performed.
  • Tumour recurrence and progression rates were determined according to the postoperative MR.
  • RESULTS: There were 16 tumour progressions in the treatment group and 12 in the control group.
  • Even residual tumour does not constitute a contraindication to GH replacement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17656592.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 9002-72-6 / Growth Hormone
  •  go-up   go-down


64. Alsaad KO, Serra S, Schmitt A, Perren A, Chetty R: Cytokeratins 7 and 20 immunoexpression profile in goblet cell and classical carcinoids of appendix. Endocr Pathol; 2007;18(1):16-22
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Goblet cell carcinoid (GCC) of the vermiform appendix is an uncommon neoplasm and its histogenesis is controversial.
  • Whether GCC represents a morphological variant of classical appendiceal carcinoid or a mucin-producing adenocarcinoma is still conjectural.
  • The tumors were also evaluated for Ki-67 proliferation index, mitotic activity, tumor necrosis, extracellular pools of mucin, obvious intestinal type adenocarcinomatous foci, angiolymphatic permeation, perineural/neural infiltration, and the depth of invasion of the appendix wall.
  • Immunohistochemically, all 17 (100%) of GCC exhibited strong and diffuse immunopositivity for CK20, whereas expression of CK7 was present in 12 cases (70.5%), ranging from 5 to 50% of tumor cells being labeled.
  • On the other hand, 25 cases of classical carcinoid tumors were consistently negative for CK7; however, 4 cases (16%) showed immunolabeling for CK20 in 25-50% of the tumor cells.
  • Goblet cell carcinoid should be regarded as a crypt cell or an amphicrine carcinoma rather than a variant of carcinoid tumor, a lesion that has benign connotations.
  • [MeSH-major] Appendiceal Neoplasms / metabolism. Carcinoid Tumor / metabolism. Goblet Cells / metabolism. Keratin-20 / metabolism. Keratin-7 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Proliferation. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):188-9 [7102895.001]
  • [Cites] Br J Surg. 2003 Nov;90(11):1317-22 [14598408.001]
  • [Cites] Differentiation. 1993 Jun;53(2):75-93 [8359595.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:13-27 [15153416.001]
  • [Cites] Mod Pathol. 2003 Dec;16(12):1189-98 [14681318.001]
  • [Cites] Endocr Pathol. 2002 Spring;13(1):47-58 [12114750.001]
  • [Cites] World J Surg Oncol. 2005 Jun 20;3:36 [15967038.001]
  • [Cites] Am J Surg Pathol. 1981 Apr;5(3):213-24 [7235117.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):729-38 [16253897.001]
  • [Cites] Am J Surg. 1994 Dec;168(6):685-7 [7978019.001]
  • [Cites] Am Surg. 2004 Jul;70(7):593-9 [15279181.001]
  • [Cites] Histopathology. 1992 Apr;20(4):345-9 [1577412.001]
  • [Cites] Histopathology. 2003 Feb;42(2):137-40 [12558745.001]
  • [Cites] Eur J Surg Oncol. 1992 Aug;18(4):386-7 [1521632.001]
  • [Cites] Ann Surg Oncol. 2006 Mar;13(3):370-6 [16485156.001]
  • [Cites] Surg Today. 2000;30(1):78-81 [10648090.001]
  • [Cites] Cancer. 1979 Nov;44(5):1700-6 [498041.001]
  • [Cites] Ann Anat Pathol (Paris). 1969 Oct-Dec;14(4):393-406 [5378353.001]
  • [Cites] J Clin Pathol. 1995 Sep;48(9):869-70 [7490325.001]
  • [Cites] Cancer. 1974 Aug;34(2):338-44 [4852178.001]
  • [Cites] Arch Pathol Lab Med. 2001 Mar;125(3):386-90 [11231488.001]
  • [Cites] Pathol Int. 2005 Aug;55(8):524-9 [15998383.001]
  • [Cites] Cancer. 1999 Jul 1;86(1):14-21 [10391558.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):271-6 [15551743.001]
  • (PMID = 17652796.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Keratin-7; 0 / Ki-67 Antigen
  •  go-up   go-down


65. Mai PL, Korde L, Kramer J, Peters J, Mueller CM, Pfeiffer S, Stratakis CA, Pinto PA, Bratslavsky G, Merino M, Choyke P, Linehan WM, Greene MH: A possible new syndrome with growth-hormone secreting pituitary adenoma, colonic polyposis, lipomatosis, lentigines and renal carcinoma in association with familial testicular germ cell malignancy: A case report. J Med Case Rep; 2007 Mar 28;1:9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Germ-cell testicular cancer has not been definitively linked to any known hereditary cancer susceptibility disorder.
  • The patient underwent genetic testing for Cowden syndrome (PTEN gene), Carney complex (PRKAR1A gene), and multiple endocrine neoplasia syndrome type 1 (MEN1 gene); no deleterious mutations were identified.
  • DISCUSSION: The constellation of benign and malignant neoplasms in the context of this patient's familial testicular cancer raised the possibility that these might be manifestations of a known hereditary susceptibility cancer syndrome; however, genetic testing for the three syndromes that were most likely to explain these findings did not show any mutation.
  • Alternatively, this family's phenotype might represent a novel neoplasm susceptibility disorder.
  • This possibility cannot be evaluated definitively on the basis of a single case report; additional observations and studies are necessary to investigate this hypothesis further.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Neurosurg. 2004 Dec;18(6):629-31 [15799199.001]
  • [Cites] Horm Res. 2004;62 Suppl 1:108-15 [15761242.001]
  • [Cites] Am J Gastroenterol. 2005 Feb;100(2):476-90 [15667510.001]
  • [Cites] Dig Dis Sci. 2004 Apr;49(4):662-6 [15185875.001]
  • [Cites] Lancet Oncol. 2004 Jun;5(6):363-71 [15172357.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):984-92 [12569597.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71 [11739416.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4041-6 [11549623.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):413-8 [10701527.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65 [16174857.001]
  • [Cites] Science. 2006 May 26;312(5777):1228-30 [16728643.001]
  • [Cites] Hum Mol Genet. 2006 Feb 1;15(3):443-51 [16407372.001]
  • (PMID = 17411461.001).
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CP / N02CP11019
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1847830
  •  go-up   go-down


66. Javle M, Shah P, Yu J, Bhagat V, Litwin A, Iyer R, Gibbs J: Cystic pancreatic tumors (CPT): predictors of malignant behavior. J Surg Oncol; 2007 Mar 1;95(3):221-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVES: Due to widespread use of imaging studies, increasing cystic pancreatic tumor (CPT) cases are being detected.
  • The diagnosis of malignancy in CPT cases requires pancreatectomy.
  • Serous cystadenoma (SCA), mucinous cystadenoma (MCA), intrapapillary mucinous tumor, cystic endocrine tumor, and lymphoepithelial cysts were classified as benign or pre-malignant.
  • CONCLUSION: Male sex, abdominal mass, weight loss, larger tumor size, local invasion, and elevated CA 19-9 were associated with malignant CPT.
  • [MeSH-major] Neoplasms, Cystic, Mucinous, and Serous / pathology. Pancreatic Cyst / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. CA-19-9 Antigen / blood. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Pancreatectomy. Retrospective Studies. Sex Factors. Weight Loss

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17323335.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


67. Illouz F, Rodien P, Saint-André JP, Triau S, Laboureau-Soares S, Dubois S, Vielle B, Hamy A, Rohmer V: Usefulness of repeated fine-needle cytology in the follow-up of non-operated thyroid nodules. Eur J Endocrinol; 2007 Mar;156(3):303-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of repeated fine-needle cytology in the follow-up of non-operated thyroid nodules.
  • OBJECTIVE: The usefulness of repeated fine-needle cytology (FNC) in thyroid nodules with benign cytology remains unknown.
  • We compared the nodules with at least one suspicious or malignant FNC (S/M nodules) with nodules with repeatedly benign (RB) FNC (RB nodules).
  • RESULTS: Among the nodules with initial benign cytology, we found 35 nodules with one or more later suspicious or malignant results.
  • The probability for a nodule to have a repeated benign FNC decreases with time and with the number of FNC.
  • We did not find any clinical or ultrasonographic characteristics related to an S/M cytology.
  • CONCLUSIONS: We suggest to repeat FNC up to three adequate samples in the follow-up of thyroid nodules so as not to miss the presence of malignant neoplasm.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Endocrinol. 2007 Jun;156(6):705. Antoine, Hamy [corrected to Hamy, Antoine]
  • (PMID = 17322489.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


68. Sahin M, Sengul A, Berki Z, Tutuncu NB, Guvener ND: Ultrasound-guided fine-needle aspiration biopsy and ultrasonographic features of infracentimetric nodules in patients with nodular goiter: correlation with pathological findings. Endocr Pathol; 2006;17(1):67-74
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytopathological results of 472 US-FNABs from 207 nodular goiter patients (170 women, 37 men; mean age, 51.5 +/- 13.1 yr) seen between 1999 and 2004 were categorized into five groups: inadequate, benign, suspicious, follicular neoplasm, and malignant.
  • In conclusion, small tumor size does not guarantee a low risk of thyroid cancer, and US-FNAB may be useful tool for diagnosing malignant infracentimetric nodules.
  • [MeSH-major] Biopsy, Fine-Needle. Carcinoma / pathology. Goiter, Nodular / pathology. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Pathol. 2003 Fall;14(3):183-91 [14586064.001]
  • [Cites] Endocrinol Metab Clin North Am. 2001 Jun;30(2):339-60, viii-ix [11444166.001]
  • [Cites] Thyroid. 1998 Jul;8(7):565-9 [9709908.001]
  • [Cites] Mayo Clin Proc. 1994 Jan;69(1):44-9 [8271850.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Jan;60(1):21-8 [14678283.001]
  • [Cites] Thyroid. 1998 Jun;8(6):511-5 [9669289.001]
  • [Cites] Thyroid. 1998 Nov;8(11):989-95 [9848711.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):1941-6 [11994321.001]
  • [Cites] Arch Surg. 1996 Feb;131(2):187-91 [8611077.001]
  • [Cites] Surgery. 1992 Dec;112(6):1139-46; discussion 1146-7 [1455316.001]
  • [Cites] Cancer. 1990 Mar 1;65(5):1173-9 [2302665.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jan;84(1):24-8 [9920057.001]
  • [Cites] Ann Intern Med. 1993 Feb 15;118(4):282-9 [8420446.001]
  • [Cites] Am J Med. 1995 Dec;99(6):642-50 [7503088.001]
  • [Cites] Med Clin North Am. 1988 Sep;72(5):1177-211 [3045454.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):31-40 [12833452.001]
  • [Cites] Yonsei Med J. 2003 Aug 30;44(4):635-40 [12950119.001]
  • [Cites] Arch Intern Med. 1994 Aug 22;154(16):1838-40 [8053752.001]
  • [Cites] World J Surg. 1996 Sep;20(7):848-53; discussion 853 [8678961.001]
  • [Cites] Thyroid. 2003 Apr;13(4):381-7 [12804106.001]
  • [Cites] J Endocrinol Invest. 2002 Mar;25(3):224-8 [11936463.001]
  • [Cites] Cancer. 1985 Aug 1;56(3):531-8 [2408737.001]
  • (PMID = 16760582.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Rody A, Holtrich U, Solbach C, Kourtis K, von Minckwitz G, Engels K, Kissler S, Gätje R, Karn T, Kaufmann M: Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer; 2005 Dec;12(4):903-16
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While early observations were often conflicting, more recent data suggest an important role as a tumor-suppressor gene.
  • A decrease of ER-beta expression has been observed in ductal carcinoma in situ and invasive carcinoma as compared with benign mammary epithelial cells.
  • In contrast to benign breast, more than two-thirds of invasive breast cancers showed a high degree of methylation.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma / genetics. DNA Methylation. Estrogen Receptor beta / genetics. Precancerous Conditions / diagnosis. Promoter Regions, Genetic / genetics
  • [MeSH-minor] Base Sequence. Biomarkers, Tumor / genetics. DNA, Neoplasm / metabolism. Epigenesis, Genetic. Female. Gene Expression Profiling. Humans. Molecular Sequence Data. Prognosis. RNA, Small Interfering / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16322330.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Estrogen Receptor beta; 0 / RNA, Small Interfering
  •  go-up   go-down


70. Molinié V, Ruffion A, Allory Y, Leroy X, Cochand Priollet B, Paraf F, de la Taille A: [Is tumour grade applicable to finasteride-treated prostate cancer?]. Prog Urol; 2005 Jun;15(3):387-91
Hazardous Substances Data Bank. FINASTERIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Is tumour grade applicable to finasteride-treated prostate cancer?].
  • [Transliterated title] Un grade tumoral est-il applicable au cancer de la prostate sous finastéride?
  • The treatment of prostate cancer by endocrine therapy induces histological changes of benign or malignant prostate glands.
  • Most authors appear to agree that cancers discovered by biopsy in patients treated with endocrine therapy should not be graded.
  • (1) the extent of histological changes after androgen deprivation endocrine therapy;.
  • [MeSH-major] Enzyme Inhibitors / therapeutic use. Finasteride / therapeutic use. Prostate / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] 5-alpha Reductase Inhibitors. Animals. Atrophy. Clinical Trials as Topic. Humans. Male. Neoplasm Staging. Prostatic Hyperplasia / drug therapy. Prostatic Hyperplasia / pathology. Prostatic Intraepithelial Neoplasia / drug therapy. Prostatic Intraepithelial Neoplasia / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16097140.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride
  • [Number-of-references] 33
  •  go-up   go-down


71. Jonkers YM, Claessen SM, Perren A, Schmid S, Komminoth P, Verhofstad AA, Hofland LJ, de Krijger RR, Slootweg PJ, Ramaekers FC, Speel EJ: Chromosomal instability predicts metastatic disease in patients with insulinomas. Endocr Relat Cancer; 2005 Jun;12(2):435-47
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endocrine pancreatic tumors (EPTs) comprise a highly heterogeneous group of tumors with different clinical behavior and genetic makeup.
  • For the identification of reliable indicators of metastatic disease, we investigated 62 sporadic insulinomas (44 benign and 18 tumors with metastases) by means of comparative genomic hybridization (CGH).
  • In addition, the role of MEN1 (multiple endocrine neoplasia type 1) gene mutations was determined to assess specific chromosomal alterations associated with dysfunction of this endocrine tumor-related tumor suppressor gene.
  • CGH analysis revealed that the total number of aberrations per tumor differs strongly between the benign and the malignant group (4.2 vs 14.1; P<0.0001).
  • Furthermore, chromosome 9q gain was found to be the most frequent aberration in both benign and malignant insulinomas, whereas chromosome 6q losses and 12q, 14q and 17pq gains are strongly associated with metastatic disease.
  • Our study shows that chromosomal instability, as defined by > or =5 gains together with > or =5 losses, or total number of gains and losses > or =8, rather than parameters such as tumor size and proliferation index, is the most powerful indicator for the development of metastatic disease in patients with sporadic insulinoma.
  • [MeSH-major] Chromosomal Instability / genetics. Insulinoma / diagnosis. Pancreatic Neoplasms / diagnosis. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Mutation. Neoplasm Metastasis. Nucleic Acid Hybridization. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947114.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MEN1 protein, human; 0 / Proto-Oncogene Proteins
  •  go-up   go-down


72. Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, Delle Fave GF, Panzuto F, Scarpa A, Falconi M: Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol; 2008 May;19(5):903-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours.
  • BACKGROUND: Non-functioning pancreatic endocrine tumours (NF-PETs) are an aggressive gastroenteropancreatic neoplasm.
  • The present study assessed survival, value of World Health Organisation (WHO) classification and prognostic utility of clinicopathological parameters at diagnosis.
  • RESULTS: There were 25 (14%) benign lesions, 38 (21%) neoplasms of uncertain behaviour, 100 well-differentiated carcinomas (56%) and 17 poorly differentiated carcinomas (9%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18209014.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


73. Fendrich V, Waldmann J, Bartsch DK, Langer P: Surgical management of pancreatic endocrine tumors. Nat Rev Clin Oncol; 2009 Jul;6(7):419-28
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of pancreatic endocrine tumors.
  • Pancreatic endocrine tumors (PETs) are uncommon but clinically challenging and fascinating tumors with an annual incidence of 1 per 100,000 people.
  • Functional tumors are commonly associated with a specific hormonal syndrome directly related to a hormone secreted by the tumor, such as Zollinger-Ellison syndrome or organic hyperinsulinism.
  • Small, benign neoplasms, such as 90% of all insulinomas, are readily curable by surgical resection; however, most other functional and all nonfunctional pancreatic tumors have a much less favorable prognosis.
  • Many features of the management of pancreatic endocrine tumors, such as timing and extent of resection, and the use of laparoscopic procedures, are currently under debate.
  • This Review describes the current status of surgical treatment for pancreatic endocrine tumors, and discusses the new developments in this field.
  • [MeSH-major] Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / surgery. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Endoscopy, Digestive System / methods. Humans. Neoplasm Staging. Pancreatectomy. Prognosis. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19506584.001).
  • [ISSN] 1759-4782
  • [Journal-full-title] Nature reviews. Clinical oncology
  • [ISO-abbreviation] Nat Rev Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 77
  •  go-up   go-down


74. Grobmyer SR, Stasik CN, Draganov P, Hemming AW, Dixon LR, Vogel SB, Hochwald SN: Contemporary results with ampullectomy for 29 "benign" neoplasms of the ampulla. J Am Coll Surg; 2008 Mar;206(3):466-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contemporary results with ampullectomy for 29 "benign" neoplasms of the ampulla.
  • Sparse data exist on procedure-related complications and the relationship between histologic analysis and outcomes.
  • STUDY DESIGN: We retrospectively reviewed our experience with ampullectomy in 29 patients with a preoperative benign histologic diagnosis over 15 years (1991 to 2006).
  • Ampullary adenomatous neoplasms were present in 89% of patients.
  • After ampullectomy (median followup=16 months), recurrences were identified in two patients (8%) with benign tumors.
  • [MeSH-major] Adenoma / surgery. Ampulla of Vater. Carcinoma / surgery. Common Bile Duct Neoplasms / pathology. Common Bile Duct Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Humans. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18308217.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Slosar M, Vohra P, Prasad M, Fischer A, Quinlan R, Khan A: Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors. Endocr Pathol; 2009;20(3):149-57
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors.
  • No significant correlation was found between pathologic tumor characteristics and IMP3 expression in differentiated follicular pattern thyroid carcinoma.
  • With 100% specificity and 69% sensitivity for FC as compared to FA and 100% specificity for FVPC, again compared to FA, IMP3 has the potential to be diagnostically useful in differentiating malignant and benign follicular pattern thyroid lesions.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Biomarkers, Tumor / analysis. Neoplasm Proteins / biosynthesis. RNA-Binding Proteins / biosynthesis. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1994 Apr;7(3):295-300 [7520169.001]
  • [Cites] J Pathol. 2005 Jul;206(3):305-11 [15852498.001]
  • [Cites] Thyroid. 2001 Dec;11(12):1101-7 [12186496.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):305-17 [15947105.001]
  • [Cites] Am J Clin Pathol. 2003 Jul;120(1):71-7 [12866375.001]
  • [Cites] Am J Surg Pathol. 2008 Feb;32(2):304-15 [18223334.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):338-42 [11301350.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1304-9 [9824112.001]
  • [Cites] Cancer. 2008 Feb 25;114(1):49-56 [18098206.001]
  • [Cites] World J Surg. 2000 Aug;24(8):913-22 [10865035.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]
  • [Cites] Hum Pathol. 2007 Aug;38(8):1178-83 [17521698.001]
  • [Cites] Pathology. 2005 Aug;37(4):296-8 [16194828.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):242-7 [17192788.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):143-50 [11789719.001]
  • [Cites] Lancet Oncol. 2006 Jul;7(7):556-64 [16814207.001]
  • [Cites] Br J Cancer. 2003 Mar 24;88(6):887-94 [12644826.001]
  • [Cites] Oncogene. 1997 Jun 5;14(22):2729-33 [9178771.001]
  • [Cites] Mech Dev. 1999 Oct;88(1):95-9 [10525192.001]
  • [Cites] Int J Surg Pathol. 2005 Jul;13(3):235-8 [16086077.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):696-702 [11710686.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):256-64 [16082252.001]
  • [Cites] Exp Oncol. 2006 Mar;28(1):70-4 [16614712.001]
  • [Cites] Mod Pathol. 2000 Aug;13(8):882-7 [10955455.001]
  • [Cites] Am J Clin Pathol. 2006 Nov;126(5):700-8 [17050067.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):213-20 [16219715.001]
  • [Cites] Mod Pathol. 1995 Oct;8(8):870-2 [8552578.001]
  • [Cites] Acta Cytol. 2008 Mar-Apr;52(2):133-8 [18499984.001]
  • [Cites] Virchows Arch. 1998 May;432(5):427-32 [9645441.001]
  • [Cites] Cancer. 2008 Jun 15;112(12):2676-82 [18412154.001]
  • [Cites] Histopathology. 2004 Nov;45(5):493-500 [15500653.001]
  • [Cites] Endocr Pathol. 2005 Winter;16(4):295-309 [16627917.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):188-95 [15644775.001]
  • [Cites] Br J Cancer. 2003 Mar 10;88(5):699-701 [12618877.001]
  • [Cites] Pathol Res Pract. 2000;196(8):533-40 [10982016.001]
  • [Cites] Endocr Pathol. 2006 Summer;17(2):109-17 [17159243.001]
  • [Cites] J Exp Med. 1999 Apr 5;189(7):1101-10 [10190901.001]
  • (PMID = 19449140.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins
  •  go-up   go-down


76. Ng VW, Ma RC, So WY, Choi KC, Kong AP, Cockram CS, Chow CC: Evaluation of functional and malignant adrenal incidentalomas. Arch Intern Med; 2010 Dec 13;170(22):2017-20
Hazardous Substances Data Bank. HYDROCORTISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We undertook this study to review the clinical characteristics of patients with adrenal incidentalomas who presented to a tertiary endocrine center in Hong Kong.
  • METHODS: Retrospective review of all 139 cases of adrenal incidentalomas that were referred to the Endocrine Centre of the Prince of Wales Hospital between June 1, 2000, and May 31, 2007.
  • We reviewed detailed patient history, physical examination findings, and symptoms and signs related to hormonal hypersecretion or malignant neoplasm and recorded clinical indications for performing diagnostic radiological imaging.
  • RESULTS: Sixty-one patients (43.9%) had nonfunctional benign adrenal adenomas, 52 (37.4%) had functional lesions, 15 (10.8%) had malignant adrenal lesions, and the remaining 11 (7.9%) had varying adrenal disease.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenocortical Adenoma / diagnosis. Aldosterone / secretion. Catecholamines / secretion. Hydrocortisone / secretion

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21149760.001).
  • [ISSN] 1538-3679
  • [Journal-full-title] Archives of internal medicine
  • [ISO-abbreviation] Arch. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Catecholamines; 4964P6T9RB / Aldosterone; 9015-71-8 / Corticotropin-Releasing Hormone; WI4X0X7BPJ / Hydrocortisone; Adrenal incidentaloma
  •  go-up   go-down


77. Kaltsas G, Androulakis II, de Herder WW, Grossman AB: Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocr Relat Cancer; 2010 Sep;17(3):R173-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroendocrine tumours may be either benign or malignant tumours, and have the ability to synthesise and secrete biologically active substances characteristic of the cell of origin that can cause distinct clinical syndromes.
  • The term 'paraneoplastic syndromes' (PNSs) is used to denote syndromes secondary to substances secreted from tumours not related to their specific organ or tissue of origin and/or production of autoantibodies against tumour cells; such syndromes are mainly associated with hormonal and neurological symptoms.
  • Appreciation of the presence of such syndromes is important as clinical presentation, if not identified, may delay the diagnosis of the underlying neoplasia.
  • Conversely, early recognition can allow for more rapid diagnosis, particularly as the coexistence of a neoplasm with a clinical or biochemical marker offers an additional determinant of tumour status/progression.
  • Their diagnosis involves a multidisciplinary approach, and detailed endocrinological, neurological, radiological and histological studies are required.
  • Correct diagnosis is essential as the treatment of choice will be different for each disorder, particularly in the case of malignant tumours; it is therefore important to develop appropriate means to correctly identify and localise these tumours.
  • Disease-specific medical therapies are mandatory in order to prevent recurrence and/or further tumour growth.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530594.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


78. Imaoka H, Yamao K, Bhatia V, Shimizu Y, Yatabe Y, Koshikawa T, Kinoshita Y: Rare pancreatic neoplasms: the utility of endoscopic ultrasound-guided fine-needle aspiration-a large single center study. J Gastroenterol; 2009;44(2):146-53
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare pancreatic neoplasms: the utility of endoscopic ultrasound-guided fine-needle aspiration-a large single center study.
  • We describe the performance and pitfalls of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) for diagnosis of these rare pancreatic tumors and their characteristic cytopathological features.
  • The reference standard for final diagnosis was surgical pathology from resected specimens.
  • Overall, EUS-FNA with the results of cytology, cell-block processing, and immunohistochemistry could correctly diagnose the type of neoplasm in 19 (67.9%) cases.
  • EUS-FNA could distinguish benign from malignant rare tumors with a sensitivity of 69.2%, a specificity of 100%, positive predictive value of 100%, negative predictive value of 79.0%, and accuracy of 85.7%.
  • None of three malignant pancreatic endocrine neoplasms could be diagnosed as malignant.
  • An adequate core tissue sample could be obtained in 21 cases (75.0%) and provide a histopathological diagnosis in 19 (67.9%) cases.
  • EUS-FNA could change the presumptive diagnosis in 11 (39.3%) cases.
  • Specific immunochemical studies were useful adjuncts to the diagnosis.
  • CONCLUSIONS: Pancreatic neoplasms other than ductal adenocarcinomas have diverse imaging and histopathological features.
  • [MeSH-major] Endosonography. Pancreatic Neoplasms / diagnostic imaging. Pancreatic Neoplasms / pathology. Surgery, Computer-Assisted

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2003 Nov;58(5):701-6 [14595305.001]
  • [Cites] Gastrointest Endosc. 1997 May;45(5):387-93 [9165320.001]
  • [Cites] Surgery. 1990 Sep;108(3):475-80 [2396191.001]
  • [Cites] J Gastrointest Surg. 2001 Jul-Aug;5(4):346-51 [11985973.001]
  • [Cites] Gastrointest Endosc. 2002 Aug;56(2):291-6 [12145615.001]
  • [Cites] Gastrointest Endosc. 2003 Nov;58(5):690-5 [14595302.001]
  • [Cites] Endoscopy. 2003 Mar;35(3):219-22 [12584640.001]
  • [Cites] Dig Dis Sci. 2002 Aug;47(8):1839-42 [12184539.001]
  • [Cites] Acta Cytol. 1992 Nov-Dec;36(6):881-6 [1449026.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1330-6 [15131794.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1386-91 [12094855.001]
  • [Cites] JOP. 2004 Jul;5(4):282-8 [15254363.001]
  • [Cites] Gastrointest Endosc. 2001 Jun;53(7):722-7 [11375578.001]
  • [Cites] Diagn Cytopathol. 1995 Oct;13(3):233-46 [8575283.001]
  • [Cites] Arch Surg. 1993 Apr;128(4):433-6 [8457156.001]
  • [Cites] Gastrointest Endosc. 1998 Feb;47(2):121-7 [9512275.001]
  • [Cites] Gastrointest Endosc. 1992 Mar-Apr;38(2):172-3 [1568614.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Oct;3(10 ):974-9 [16234042.001]
  • [Cites] J Surg Oncol. 2003 Jul;83(3):161-6; discussion 166 [12827684.001]
  • [Cites] Gastrointest Endosc. 2005 Jan;61(1):76-9 [15672060.001]
  • [Cites] Acta Cytol. 1991 Sep-Oct;35(5):546-8 [1927196.001]
  • [Cites] Diagn Cytopathol. 2004 Nov;31(5):313-8 [15468134.001]
  • [Cites] Gastrointest Endosc. 2004 Aug;60(2):267-79 [15278063.001]
  • [Cites] Am J Clin Pathol. 2004 May;121(5):654-62 [15151205.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):35-40 [11833495.001]
  • [Cites] Gastrointest Endosc. 2005 May;61(6):689-96 [15855973.001]
  • [Cites] Am J Surg. 2001 Aug;182(2):183-4 [11574093.001]
  • [Cites] Gut. 2000 Feb;46(2):244-9 [10644320.001]
  • [Cites] Gastrointest Endosc. 2001 Jan;53(1):65-70 [11154491.001]
  • [Cites] Gastrointest Endosc. 2003 Nov;58(5):784-8 [14595324.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] Cancer. 2002 Jun 25;96(3):174-80 [12115306.001]
  • [Cites] Pancreas. 2006 Mar;32(2):223-4 [16552347.001]
  • [Cites] Am J Gastroenterol. 2002 Nov;97(11):2768-75 [12425546.001]
  • (PMID = 19214677.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


79. Tse GM, Tan PH, Moriya T: The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast. J Clin Pathol; 2009 May;62(5):407-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast.
  • Correct diagnosis is crucial but may be difficult, as many benign and malignant papillary lesions have similar appearances.
  • In intracystic papillary carcinoma, there is controversy as to the presence of a complete myoepithelial cell layer around these lesions. p63 is the marker of choice as the staining is nuclear, cross-reactivity is minimal, and sensitivity is high.
  • Neuroendocrine markers (chromogranin A and synaptophysin) may be positive in papillary carcinoma, particularly in the solid type, and there may be some overlap with the ductal carcinoma in situ with spindle cells or endocrine ductal carcinoma in situ.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Papillary / diagnosis. Papilloma / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Diagnosis, Differential. Female. Humans. Keratins / analysis. Neoplasm Proteins / analysis. Nerve Tissue Proteins / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19126567.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 68238-35-7 / Keratins
  • [Number-of-references] 33
  •  go-up   go-down


80. Sugimoto M, Yasuda H, Koda K, Suzuki M, Yamazaki M, Tezuka T, Kosugi C, Higuchi R, Takenoue T, Yamamoto S, Watayo Y, Yagawa Y, Tsuchiya T: Virtual CO2 MDCT pancreatography: a new feasible technique for minimally invasive pancreatectomy in intraductal papillary mucinous neoplasms. Hepatogastroenterology; 2008 Jan-Feb;55(81):270-4
Hazardous Substances Data Bank. Carbon dioxide .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Virtual CO2 MDCT pancreatography: a new feasible technique for minimally invasive pancreatectomy in intraductal papillary mucinous neoplasms.
  • BACKGROUND/AIMS: Less invasive pancreatic head resection, such as duodenum-preserving pancreatic head resection (DPPHR) has been introduced for the treatment of pancreatoduodenal lesions, especially for benign conditions, for reducing surgical stress and maintaining exocrine and endocrine function of the residual pancreas in consideration of postoperative quality of life (QOL).
  • METHODOLOGY: We investigated the feasibility of a new technique employing three-dimensional (3D) virtual pancreatography using multi-detector CT (MDCT) with carbon dioxide (CO2) gas as a negative contrast agent for detection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas requiring minimally invasive surgery.
  • For localizing diagnosis of these small and multiple pancreatic cysts, we placed an endoscopic pancreatic stent (EPS), and MDCT with injection of CO2 via EPS was examined for the virtual CO2 pancreatography, consisting of OsiriX software system employing 3D virtual anatomic reconstruction with CO2 gas as a negative contrast agent.
  • We performed DPPHR, and surgical margin of the patient's remnant pancreas was determined as non-malignant by intraoperative histology.
  • There was no residual pancreatic cyst and tumor after surgery.
  • The resected tumor was diagnosed as branch duct type intraductal papillary mucinous adenocarcinoma.
  • According to our minimally invasive DPPHR obtained by virtual CO2 pancreatography, the pancreatic endocrine and exocrine functions of this patient were maintained at almost the same levels as those in his preoperative status.
  • With respect to preservation of the endocrine and exocrine functions of the pancreas, DPPHR is a highly effective surgical procedure due to limited surgical resection.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / surgery. Carcinoma, Pancreatic Ductal / radiography. Carcinoma, Pancreatic Ductal / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / radiography. Pancreatic Neoplasms / surgery. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507123.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide
  •  go-up   go-down


81. Clemente G, Sarno G, Giordano M, De Rose AM, Giovannini I, Vecchio FM, Nuzzo G: Total gastrectomy for type 1 gastric carcinoid: an unusual surgical indication? Minerva Chir; 2007 Oct;62(5):421-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastric carcinoid is a relatively rare neoplasm with peculiar features which differentiate it from the intestinal and pulmonary carcinoid and, obviously, from gastric adenocarcinoma.
  • Gastric carcinoids are divided into three different types: Type 1, associated with gastric atrophy and megaloblastic anemia; Type 2, associated with Zollinger-Ellison syndrome within a type 1 multiple endocrine neoplasia (MEN); and Type 3, sporadic tumor not associated with other lesions, particularly invasive and with poor prognosis.
  • It is generally small, multifocal and located in the gastric fundus, has no tendency for vascular invasion and is associated with a benign course.
  • We report a case of a woman with a type 1 gastric carcinoid in which, for the presence of an extended micro-polyposis of the fundus a total gastrectomy was necessary for treatment.
  • [MeSH-major] Carcinoid Tumor / surgery. Gastrectomy. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17947953.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


82. Miyamoto H, Molena DA, Schoeniger LO, Haodong Xu: Solitary fibrous tumor of the pancreas: a case report. Int J Surg Pathol; 2007 Jul;15(3):311-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the pancreas: a case report.
  • Solitary fibrous tumor (SFT) is an unusual mesenchymal neoplasm that most often arises in the pleura; however, it has recently been described in a number of extrapleural sites.
  • This report describes an extremely rare case of a benign SFT arising in the pancreas.
  • An endocrine tumor was clinically suspected.
  • Microscopically, the tumor was composed of bland uniform spindle cells arranged between collagen bundles.
  • Based on the light microscopic morphology and immunohistochemical staining profile, the diagnosis of SFT was rendered.
  • [MeSH-major] Neoplasms, Fibrous Tissue / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17652547.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


83. Kijima Y, Yoshinaka H, Owaki T, Aikou T: Early experience of immediate reconstruction using autologous free dermal fat graft after breast conservational surgery. J Plast Reconstr Aesthet Surg; 2007;60(5):495-502
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immediate reconstruction of the surgical defect was performed in seven Japanese women using autologous free dermal fat graft (FDFG) from the lower abdomen after breast-conserving surgeries for six malignant lesions and two benign masses located in the medial or central area of the breasts.
  • [MeSH-major] Adipose Tissue / transplantation. Breast Neoplasms / surgery. Carcinoma, Ductal, Breast / surgery. Mammaplasty / methods
  • [MeSH-minor] Adult. Aged. Breast / pathology. Breast / surgery. Female. Humans. Mastectomy, Segmental. Middle Aged. Neoplasm Invasiveness. Skin Transplantation / methods. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Reconstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17399658.001).
  • [ISSN] 1748-6815
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


84. Alasio TM, Vine A, Sanchez MA, Dardik H: Pancreatic endocrine tumor coexistent with serous microcystic adenoma: report of a case and review of the literature. Ann Diagn Pathol; 2005 Aug;9(4):234-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endocrine tumor coexistent with serous microcystic adenoma: report of a case and review of the literature.
  • Serous cystadenomas of the pancreas have been classified as benign exocrine tumors.
  • There have been rare cases of malignant behavior, and in exceptional cases, coexisting neoplasms have been reported.
  • We report a case of a coexistent neuroendocrine tumor identified within a serous cystadenoma in a 78-year-old woman, which was discovered incidentally after complete resection of the tumor.
  • Given the unpredictable metastatic potential of neuroendocrine tumors of the pancreas, we advocate complete resection of all pancreatic cystic tumors, combined with careful sampling of the pathological specimen to rule out a coexistent potentially malignant neoplasm.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Cystadenoma, Serous / pathology. Neoplasms, Multiple Primary / pathology. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic adenoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16084460.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Perrier ND, Kennamer DL, Bao R, Jimenez C, Grubbs EG, Lee JE, Evans DB: Posterior retroperitoneoscopic adrenalectomy: preferred technique for removal of benign tumors and isolated metastases. Ann Surg; 2008 Oct;248(4):666-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posterior retroperitoneoscopic adrenalectomy: preferred technique for removal of benign tumors and isolated metastases.
  • OBJECTIVE: Posterior retroperitoneoscopic adrenalectomy (PRA) is a minimally invasive approach to removal of the adrenal gland.
  • METHODS: The prospective endocrine surgery database at a tertiary care center was used to capture all patients who underwent PRA between October 2005 and February 2008.
  • Mean tumor size was 3.4 cm.
  • PRA may be the preferred technique for removing benign adrenal tumors and isolated metastases.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Laparoscopy / methods. Retroperitoneal Space / surgery
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18936580.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


86. Fasanella KE, McGrath KM, Sanders M, Brody D, Domsic R, Khalid A: Pancreatic endocrine tumor EUS-guided FNA DNA microsatellite loss and mortality. Gastrointest Endosc; 2009 May;69(6):1074-80
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endocrine tumor EUS-guided FNA DNA microsatellite loss and mortality.
  • BACKGROUND: The clinical course of pancreatic endocrine tumors (PET) depends on tumor size, the presence of invasion or metastasis, the Ki-67 index, mitoses per high power field, and mutational damage.
  • OBJECTIVE: To evaluate PET EUS-guided FNA (EUS-FNA) microsatellite loss analysis in the context of PET-related mortality.
  • Malignant PET contained multiple microsatellite losses, with a median fractional allelic loss (FAL) of 0.37 (range 0.12-0.69, interquartile range [IQR] 0.23-0.42), significantly different from benign PET, median FAL 0 (range 0-0.18, IQR 0-0.08, P < .0001).
  • [MeSH-major] Biopsy, Fine-Needle. Carcinoma, Islet Cell / genetics. Carcinoma, Islet Cell / ultrasonography. Endosonography. Loss of Heterozygosity / genetics. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / ultrasonography. Ultrasonography, Interventional
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Ki-67 Antigen / genetics. Male. Middle Aged. Neoplasm Staging. Pancreas / pathology. Pancreas / ultrasonography. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastrointest Endosc. 2009 May;69(6):1081-4 [19410041.001]
  • (PMID = 19152901.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


87. Ito Y, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A: Prognosis of patients with benign thyroid diseases accompanied by incidental papillary carcinoma undetectable on preoperative imaging tests. World J Surg; 2007 Aug;31(8):1672-6
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of patients with benign thyroid diseases accompanied by incidental papillary carcinoma undetectable on preoperative imaging tests.
  • BACKGROUND: Despite the recent wide availability of ultrasonography and fine-needle aspiration biopsy, endocrine surgeons often encounter incidental papillary carcinoma (IPC), that is a papillary carcinoma that had gone undetected by preoperative imaging studies but was identified by pathological examination of surgical specimens resected for benign thyroid diseases.
  • METHODS: The present study was developed to investigate the prognoses of 317 patients who underwent surgery for benign diseases involving IPC in comparison with the prognoses of 1,674 patients with clinically apparent papillary carcinoma detected preoperatively and diagnosed.
  • RESULTS: None of the patients underwent further surgery such as completion total thyroidectomy and node dissection immediately after the diagnosis of IPC.
  • CONCLUSIONS: Because IPC is associated with good prognosis, further surgery, such as completion total thyroidectomy or lymph node dissection immediately after the diagnosis of IPC is not necessary.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Incidental Findings. Longitudinal Studies. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Survival Analysis. Thyroid Diseases / surgery. Thyroidectomy. Treatment Outcome. Unnecessary Procedures

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Clin Cancer Res. 2005 Jun;24(2):231-6 [16110756.001]
  • [Cites] Cancer. 1975 Sep;36(3):1095-9 [1182663.001]
  • [Cites] Eur J Surg. 1997 Apr;163(4):255-9 [9161822.001]
  • [Cites] Pathol Int. 2003 Sep;53(9):579-83 [14507313.001]
  • [Cites] World J Surg. 1991 Jul-Aug;15(4):511-5 [1891937.001]
  • [Cites] World J Surg. 2004 Nov;28(11):1115-21 [15490053.001]
  • [Cites] Am Surg. 2005 Nov;71(11):911-3; discussion 913-5 [16372608.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Nov;63(5):577-81 [16268811.001]
  • [Cites] ANZ J Surg. 2006 Mar;76(3):123-6 [16626346.001]
  • [Cites] Surgery. 1992 Dec;112(6):1139-46; discussion 1146-7 [1455316.001]
  • [Cites] Endocr J. 1999 Feb;46(1):209-16 [10426589.001]
  • [Cites] Presse Med. 2000 Nov 25;29(36):1969-72 [11149075.001]
  • [Cites] Arch Surg. 2005 Oct;140(10 ):981-5 [16230549.001]
  • [Cites] Thyroid. 2003 Apr;13(4):381-7 [12804106.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):399-407 [12616125.001]
  • [Cites] Cancer. 2005 Aug 25;105(4):217-9 [15986395.001]
  • [Cites] Pathol Res Pract. 1992 Aug;188(6):747-50 [1437838.001]
  • [Cites] Cancer. 1985 Aug 1;56(3):531-8 [2408737.001]
  • [Cites] Arch Pathol. 1971 Apr;91(4):334-9 [5549711.001]
  • [Cites] Am J Clin Pathol. 1988 Jul;90(1):72-6 [3389346.001]
  • (PMID = 17571205.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Vogelsang H, Siewert JR: Endocrine tumours of the hindgut. Best Pract Res Clin Gastroenterol; 2005 Oct;19(5):739-51
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine tumours of the hindgut.
  • Therapeutic algorithms are proposed depending mainly on analogous TNM categories and grading considering conventional and experimental surgical and non-surgical therapy.
  • As most rectal neuroendocrine tumours are benign because of submucosal extension only, the size and infiltration depth correlates with lymph-node and distant metastases and therefore with the prognosis.
  • It is unknown whether endoscopic ultrasound can improve the diagnostic accuracy compared to size-related conclusions, and therefore whether it can change therapeutic strategies and improve survival by modern rectal surgery.
  • [MeSH-major] Colectomy / methods. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / surgery
  • [MeSH-minor] Anastomosis, Surgical. Biopsy, Needle. Colonoscopy / methods. Female. Humans. Incidence. Male. Neoplasm Staging. Prognosis. Rare Diseases. Risk Assessment. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253898.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 37
  •  go-up   go-down


89. Jonmarker S, Glaessgen A, Culp WD, Pisa P, Lewensohn R, Ekman P, Valdman A, Egevad L: Expression of PDX-1 in prostate cancer, prostatic intraepithelial neoplasia and benign prostatic tissue. APMIS; 2008 Jun;116(6):491-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of PDX-1 in prostate cancer, prostatic intraepithelial neoplasia and benign prostatic tissue.
  • Pancreatic duodenal homeobox 1 (PDX-1), a Hox type transcription factor, is necessary for differentiation of exocrine and endocrine pancreas, and regulates insulin gene transcription.
  • We separately arrayed benign prostatic tissue, atrophy, high-grade prostatic intraepithelial neoplasia (HGPIN) and PCa from 40 men and also 17 lymph node metastases.
  • PDX-1 was overexpressed in cancer vs benign tissue (p<0.001), but also in atrophy and HGPIN vs cancer (p<0.001 and p=0.022, respectively).
  • Presence of PDX-1 protein in benign and malignant prostatic tissue was confirmed by Western blot.
  • [MeSH-major] Homeodomain Proteins / metabolism. Prostate / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Intraepithelial Neoplasia / metabolism. Prostatic Neoplasms / metabolism. Trans-Activators / metabolism
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Neoplasm Metastasis. Tissue Array Analysis. Up-Regulation

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18754323.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Trans-Activators; 0 / pancreatic and duodenal homeobox 1 protein
  •  go-up   go-down


90. Delle Fave G, Capurso G, Milione M, Panzuto F: Endocrine tumours of the stomach. Best Pract Res Clin Gastroenterol; 2005 Oct;19(5):659-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine tumours of the stomach.
  • Gastric endocrine tumours (gastric carcinoids) usually grow from enterochromaffin-like (ECL) cells.
  • Three types of tumour may be distinguished on the basis of the background gastric pathology: type I, which develops in atrophic body gastritis (ABG); type II, which is associated with multiple endocrine neoplasia and Zollinger-Ellison syndrome; and the sporadic type III, which is not associated with any background pathology.
  • In fact, type I carcinoids can be considered to be benign lesions, with exceptional risk of metastases.
  • [MeSH-major] Carcinoid Tumor / epidemiology. Carcinoid Tumor / pathology. Neoplasm Invasiveness / pathology. Stomach Neoplasms / epidemiology. Stomach Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Female. Gastrectomy / methods. Gastric Mucosa / pathology. Gastroscopy / methods. Humans. Immunohistochemistry. Incidence. Male. Neoplasm Staging. Prognosis. Risk Assessment. Survival Rate. Treatment Outcome. Zollinger-Ellison Syndrome / epidemiology. Zollinger-Ellison Syndrome / pathology. Zollinger-Ellison Syndrome / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253892.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 63
  •  go-up   go-down


91. Mathur A, Weng J, Moses W, Steinberg SM, Rahbari R, Kitano M, Khanafshar E, Ljung BM, Duh QY, Clark OH, Kebebew E: A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine needle aspiration biopsy. Surgery; 2010 Dec;148(6):1170-6; discussion 1176-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Clinical, tumor genotyping for common somatic mutations (BRAF V600E, NRAS, KRAS, RET/PTC1, RET/PTC3, and NTRK1), and the gene expression levels of 6 candidate diagnostic markers were analyzed by univariate and multivariate methods in 341 patients to determine whether they could distinguish reliably benign from malignant thyroid neoplasms, and a scoring model was derived.
  • RESULTS: By a multivariate analysis, fine needle aspiration biopsy cytology classification, the presence of a NRAS mutation, and the tissue inhibitor of metalloproteinase 1 expression level were associated jointly with malignancy.
  • The overall accuracy of the scoring model, including these 3 variables, to distinguish benign from malignant thyroid tumors was 91%, including 67% for the indeterminate and 77% for the suspicious FNA subgroups.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Thyroid Diseases / pathology. Thyroid Gland / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Ethnic Groups. Female. Genes, ras / genetics. Humans. Male. Medical History Taking. Middle Aged. Multivariate Analysis. Mutation. Prospective Studies. RNA / genetics. RNA / isolation & purification. RNA, Neoplasm / genetics. RNA, Neoplasm / isolation & purification. Reproducibility of Results. Thyroidectomy / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Mosby, Inc.
  • [Cites] Cancer. 2000 Dec 25;90(6):357-63 [11156519.001]
  • [Cites] Am J Clin Pathol. 2001 Oct;116(4):477-82 [11601131.001]
  • [Cites] Arch Surg. 2002 Jul;137(7):818-21 [12093339.001]
  • [Cites] Endocr Pract. 2003 Mar-Apr;9(2):128-36 [12917075.001]
  • [Cites] Ann Intern Med. 1968 Sep;69(3):537-40 [5673172.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2592-7 [16688775.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 May;66(5):678-83 [17381488.001]
  • [Cites] Curr Opin Oncol. 2008 Jan;20(1):13-8 [18043251.001]
  • [Cites] Cancer. 2009 Mar 1;115(5):972-80 [19152441.001]
  • [Cites] CA Cancer J Clin. 2009 Mar-Apr;59(2):99-110 [19278960.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jun;94(6):2092-8 [19318445.001]
  • [Cites] J Clin Oncol. 2009 Jun 20;27(18):2977-82 [19414674.001]
  • [Cites] Diagn Cytopathol. 2009 Oct;37(10):710-4 [19373907.001]
  • [Cites] Surg Clin North Am. 2009 Oct;89(5):1139-55 [19836489.001]
  • [Cites] Surgery. 2009 Dec;146(6):1215-23 [19958951.001]
  • [Cites] Curr Opin Oncol. 2010 Jan;22(1):23-9 [19907326.001]
  • [Cites] Thyroid. 2009 Dec;19(12):1351-61 [19895341.001]
  • [Cites] Mol Cell Endocrinol. 2010 May 28;321(1):77-85 [19932149.001]
  • [Cites] J Surg Res. 2010 May 15;160(2):179-83 [19765726.001]
  • [Cites] Mol Cell Endocrinol. 2010 Jun 30;322(1-2):8-28 [20138116.001]
  • [ErratumIn] Surgery. 2012 Feb;151(2):343. Rahabari, Reza [corrected to Rahbari, Reza]
  • (PMID = 21134548.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Neoplasm; 63231-63-0 / RNA
  • [Other-IDs] NLM/ NIHMS240002; NLM/ PMC3052943
  •  go-up   go-down


92. Adam N, Lim SS, Ananda V, Chan SP: VIPoma syndrome: challenges in management. Singapore Med J; 2010 Jul;51(7):e129-32
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vasoactive intestinal peptide-producing tumour (VIPoma) or Verner-Morrison syndrome is a very rare neuroendocrine tumour.
  • Diagnosis is characteristically delayed.
  • It may be curative in forty percent of patients with benign and non-metastatic disease.
  • Somatostatin analogues improve hormone-mediated symptoms, reduce tumour bulk and prevent local and systemic effects.
  • We present a female patient with VIPoma syndrome, which had metastasised to the liver at diagnosis.
  • [MeSH-major] Liver Neoplasms / secondary. Palliative Care. Pancreatic Neoplasms / pathology. Vipoma / secondary
  • [MeSH-minor] Catheter Ablation / methods. Combined Modality Therapy. Disease Progression. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Octreotide / therapeutic use. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - VIPoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20730389.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] RWM8CCW8GP / Octreotide
  •  go-up   go-down


93. Fendrich V, Bartsch DK: [Diagnosis and surgical management of neureondocrine pancreatic tumours]. Zentralbl Chir; 2010 Jun;135(3):210-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and surgical management of neureondocrine pancreatic tumours].
  • The only chance of cure for patients with pancreatic endocrine tumours (PETs) is complete surgical removal not only of the primary tumour, but also of local or distant metastases.
  • This is true for gastrinomas, vipomas, glucagonomas, somatostatinomas and non-functional pancreatic endocrine tumours.
  • An aggressive surgical approach leads to cure in patients with benign tumours, and may achieve long-term survival in patients with malignant NPTs.
  • [MeSH-major] Hyperinsulinism / surgery. Insulinoma / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Laparoscopy. Lymph Node Excision. Male. Middle Aged. Minimally Invasive Surgical Procedures. Neoplasm Staging. Pancreas / pathology. Pancreas / surgery. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag Stuttgart, New York.
  • (PMID = 20549584.001).
  • [ISSN] 1438-9592
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


94. Clerici T, Kolb W, Beutner U, Bareck E, Dotzenrath C, Kull C, Niederle B, German Association of Endocrine Surgeons: Diagnosis and treatment of small follicular thyroid carcinomas. Br J Surg; 2010 Jun;97(6):839-44
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of small follicular thyroid carcinomas.
  • METHODS: Members of the German Association of Endocrine Surgeons were asked to review patients with mFTC operated on between 1990 and 2005.
  • Most initial diagnoses had to be revised because of incorrect size assessment or incorrect diagnosis (benign adenoma, papillary thyroid carcinoma (PTC), follicular variant of PTC).
  • The diagnosis of mFTC was confirmed in only four patients.
  • As a result of the incorrect histopathological diagnosis, unnecessary completion thyroidectomy and radioiodine ablation were performed in 17 and 20 patients respectively.
  • Histopathological re-evaluation by an experienced pathologist is recommended before embarking on further treatments when a diagnosis of mFTC is made.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Thyroid Neoplasms / pathology. Thyroid Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Austria. Female. Germany. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Switzerland. Thyroidectomy. Tumor Burden

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20473996.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Investigator] Kaserer K; Perren A; Schmid KW; Köberle-Wührer R; Wenzl E; Asari R; Klinge U; Müller G; Kroell KP; Blankenburg C; Voss H; Cupisti K; Witte J; Knoefel WT; Simon D; Lienenlüke RH; Vorländer C; Wacha H; Schabram J; Lorenz K; Dralle H; Wojciechowski B; Kussmann J; Weber Y; Schürmann G; Goretzki PE; Ulitzer H; Eberle A; Mayer M; Stabenow R; Stegmaier C; Bühlmann R; Schlumpf R; Triponez F; Ess SM
  •  go-up   go-down


95. Fenske W, Völker HU, Adam P, Hahner S, Johanssen S, Wortmann S, Schmidt M, Morcos M, Müller-Hermelink HK, Allolio B, Fassnacht M: Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer; 2009 Sep;16(3):919-28
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accelerated glycolysis is a characteristic feature of cancer cells and in a variety of tumour entities key factors in glucose metabolism like glucose transporter 1 and 3 (GLUT1 and -3), transketolase like-1 enzyme (TKTL1) and pyruvate kinase type M2 (M2-PK) are overexpressed and of prognostic value.
  • Immunohistochemical analysis was performed on tissue microarrays of paraffin-embedded tissue samples from 167 ACCs, 15 adrenal adenomas and 4 normal adrenal glands.
  • GLUT1 and -3 were expressed in 33 and 17% of ACC samples respectively, but in none of the benign tumours or normal adrenals glands.
  • By contrast, TKTL1 and M2-PK were detectable in all benign tissues and the vast majority of ACCs.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / diagnosis. Adrenocortical Carcinoma / metabolism. Glucose Transporter Type 1 / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Biomarkers, Tumor / physiology. Female. Glucose / metabolism. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. GLUCOSE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19465749.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / SLC2A1 protein, human; IY9XDZ35W2 / Glucose
  •  go-up   go-down


96. Sassolas G, Hafdi-Nejjari Z, Remontet L, Bossard N, Belot A, Berger-Dutrieux N, Decaussin-Petrucci M, Bournaud C, Peix JL, Orgiazzi J, Borson-Chazot F: Thyroid cancer: is the incidence rise abating? Eur J Endocrinol; 2009 Jan;160(1):71-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They were fortuitously discovered after thyroidectomy for benign diseases in 64% of cases.
  • Histological marks of aggressiveness differed according to the size of the tumor.
  • Despite recent advances in diagnosis, 13% of tumors were diagnosed at advanced stage especially in men.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18952764.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


97. Pugliese R, Maggioni D, Sansonna F, Scandroglio I, Forgione A, Boniardi M, Costanzi A, Citterio D, Ferrari GC, Lernia SD, Magistro C: Laparoscopic distal pancreatectomy: a retrospective review of 14 cases. Surg Laparosc Endosc Percutan Tech; 2008 Jun;18(3):254-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the role of minimally invasive techniques in pancreatic surgery remains controversial, resection of the left pancreas for benign or endocrine lesions has been universally adopted as a routine technique over the last few years.
  • This study was undertaken to assess feasibility and safety of minimal access resections of distal pancreas in benign, endocrine, and malignant diseases.
  • From the years 2002 to 2007, 14 patients affected by pancreatic neoplasm of body/tail region were approached by minimally invasive technique.
  • Nine patients were affected by malignant neoplasms and distal splenopancreatectomy was successfully achieved by laparoscopy in 6.
  • Five patients were affected by endocrine neoplasms; distal pancreatectomy with preservation of spleen and splenic vessels was achieved laparoscopically in 3, whereas 2 needed conversion to laparotomy.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / surgery. Laparoscopy. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18574411.001).
  • [ISSN] 1530-4515
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Leskelä S, Honrado E, Montero-Conde C, Landa I, Cascón A, Letón R, Talavera P, Cózar JM, Concha A, Robledo M, Rodríguez-Antona C: Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer. Endocr Relat Cancer; 2007 Sep;14(3):645-54
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus, we measured CYP3A4, CYP3A5, CYP3A7, and CYP3A43 mRNA in 14 benign prostatic hyperplasias and ten matched non-tumoral/tumoral prostate samples.
  • We found that CYP3A5 mRNA in non-tumoral prostate tissue was 10% of the average amount of liver samples, whereas the expression of the other CYP3A genes was much lower.
  • CYP3A5 protein was detected in non-tumoral prostate microsomes by western blot, and immunohistochemistry (IHC) localized CYP3A5 exclusively in the basolateral prostate cells.
  • This finding supports an endogenous function of CYP3A5 related to the metabolism of intra-prostatic androgens and cell growth, and that polymorphisms affecting CYP3A5 activity may result in altered prostate cancer risk and aggressiveness.
  • [MeSH-major] Carcinoma / genetics. Cytochrome P-450 Enzyme System / genetics. Cytochrome P-450 Enzyme System / metabolism. Prostate / metabolism. Prostatic Neoplasms / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Cytochrome P-450 CYP3A. Down-Regulation. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Staging. Polymorphism, Genetic. Prostatic Hyperplasia / genetics. Prostatic Hyperplasia / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914095.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / CYP3A5 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A
  •  go-up   go-down


99. Ouaïssi M, Sielezneff I, Alves A, Pirro N, Heyries L, Robitail S, Consentino B, Payan MJ, Valleur P, Panis Y, Sastre B: [Long term outcome following 26 surgical ampullectomies]. Ann Chir; 2006 May;131(5):322-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Résultat à long terme de 26 ampullectomies chirurgicales.
  • Ampullectomy is an alternative to PD for benign ampulloma or, in high-risk patients, for invasive carcinoma.
  • The aim of this study was to report early and long term results of surgical ampullectomy for presumed benign ampullomas.
  • RESULTS: Final pathological examination revealed 15 adenomas, 4 in situ adenocarcinomas, 2 endocrine tumors, and 5 other benign lesions.
  • CONCLUSION: Ampullectomy is a good alternative to PD in case of benign or non-invasive malignant ampullary lesion, including in selected cases of FAP.
  • [MeSH-major] Ampulla of Vater / surgery. Common Bile Duct Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / surgery. Adenoma / surgery. Adenomatous Polyposis Coli / surgery. Adult. Aged. Carcinoma in Situ / surgery. Cause of Death. Common Bile Duct Diseases / surgery. Female. Follow-Up Studies. Granuloma, Plasma Cell / surgery. Humans. Longitudinal Studies. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Retrospective Studies. Somatostatinoma / surgery. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16615931.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


100. Cañizares MA, García-Fontán EM, Rivo JE, Gonzalez-Piñeiro A: Local recurrence and metastatic disease in a typical N1 carcinoid bronchial tumour. Clin Transl Oncol; 2005 Jun;7(5):216-8
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local recurrence and metastatic disease in a typical N1 carcinoid bronchial tumour.
  • Typical carcinoid bronchial tumour is a well-known disease that, for years, was considered benign.
  • Currently, it is classified within the group of neuro-endocrine lung tumours.
  • It is a low-grade malignancy tumour with a capability of local and distant recurrence.
  • We present, here, a case of a 19-years-old female diagnosed as having N1-bronchial typical carcinoid tumour.
  • [MeSH-major] Bronchial Neoplasms / pathology. Carcinoid Tumor / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasma. 2003;50(1):60-5 [12687280.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):463-8 [14713259.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Jan;107(1):1-6; discussion 6-7 [8283871.001]
  • [Cites] J Thorac Cardiovasc Surg. 2002 Feb;123(2):303-9 [11828290.001]
  • [Cites] Arch Bronconeumol. 1998 Feb;34(2):71-5 [9557178.001]
  • [Cites] Lung Cancer. 2004 Jan;43(1):39-45 [14698535.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Dec;59(6):793-9 [14974924.001]
  • [Cites] Ann Thorac Surg. 2003 Dec;76(6):1838-42 [14667595.001]
  • [Cites] Hepatogastroenterology. 1999 Sep-Oct;46(29):2961-4 [10576382.001]
  • [Cites] Eur J Cardiothorac Surg. 2000 Sep;18(3):301-6 [10973539.001]
  • [Cites] Ann Thorac Surg. 2000 Jul;70(1):258-63 [10921719.001]
  • [Cites] J Gastrointest Surg. 2004 Feb;8(2):208-12 [15036197.001]
  • [Cites] Am J Surg. 2004 Jan;187(1):39-46 [14706584.001]
  • (PMID = 15960934.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down






Advertisement